

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS	4	MAY 10	CA/CAPLUS enhanced with 1900-1906 U.S. patent records
NEWS	5	MAY 11	KOREAPAT updates resume
NEWS	6	MAY 19	Derwent World Patents Index to be reloaded and enhanced
NEWS	7	MAY 30	IPC 8 Rolled-up Core codes added to CA/CAPLUS and USPATFULL/USPAT2
NEWS	8	MAY 30	The F-Term thesaurus is now available in CA/CAPLUS
NEWS	9	JUN 02	The first reclassification of IPC codes now complete in INPADOC
NEWS	10	JUN 26	TULSA/TULSA2 reloaded and enhanced with new search and and display fields
NEWS	11	JUN 28	Price changes in full-text patent databases EPFULL and PCTFULL
NEWS	12	JUL 11	CHEMSAFE reloaded and enhanced
NEWS	13	JUL 14	FSTA enhanced with Japanese patents
NEWS	14	JUL 19	Coverage of Research Disclosure reinstated in DWPI
NEWS	15	AUG 09	INSPEC enhanced with 1898-1968 archive
NEWS	16	AUG 28	ADISCTI Reloaded and Enhanced
NEWS	17	AUG 30	CA(SM)/CAPLUS(SM) Austrian patent law changes
NEWS	18	SEP 11	CA/CAPLUS enhanced with more pre-1907 records
NEWS EXPRESS		JUNE 30	CURRENT WINDOWS VERSION IS V8.01b, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8
NEWS X25			X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 09:00:46 ON 21 SEP 2006

=> file reg

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 09:01:11 ON 21 SEP 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 20 SEP 2006 HIGHEST RN 908067-83-4  
DICTIONARY FILE UPDATES: 20 SEP 2006 HIGHEST RN 908067-83-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

Effective September 24, 2006, Concord 3D coordinates will no longer  
be available. Please contact CAS Customer Care  
(<http://www.cas.org/supp.html>) if you have a need for 3D coordinates.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> e oxamflatin/cn

E1	1	OXAMETHONIUM/CN
E2	1	OXAMETHONIUM IODIDE/CN
E3	1 -->	OXAMFLATIN/CN
E4	1	OXAMIC ACID/CN
E5	1	OXAMIC ACID AMIDE/CN
E6	1	OXAMIC ACID CHLORIDE/CN
E7	1	OXAMIC ACID HYDRAZIDE/CN
E8	1	OXAMIC ACID, (((CARBOXYMETHYL) CARBAMOYL) METHYL) -/CN
E9	1	OXAMIC ACID, ((3-AMINOPYRAZINYL) METHYL) -, ETHYL ESTER/CN
E10	1	OXAMIC ACID, ((4-AMINO-2-ETHYL-5-PYRIMIDINYL) METHYL) -/CN
E11	1	OXAMIC ACID, ((4-AMINO-2-ETHYL-5-PYRIMIDINYL) METHYL) -, ETHYL ESTER/CN
E12	1	OXAMIC ACID, ((4-AMINO-2-ETHYL-5-PYRIMIDINYL) METHYL) THIO- (( C7H10N3)NHCSCOOH)/CN

=> e3

L1 1 OXAMFLATIN/CN

=> d 11

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN

RN 151720-43-3 REGISTRY

ED Entered STN: 14 Dec 1993

CN 2-Penten-4-ynamide, N-hydroxy-5-[3-[(phenylsulfonyl)amino]phenyl]-, (2E)-  
(9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 2-Penten-4-ynamide, N-hydroxy-5-[3-[(phenylsulfonyl)amino]phenyl]-, (E)-

OTHER NAMES:


CN Oxamflatin

FS STEREOSEARCH

MF C17 H14 N2 O4 S

SR CA  
LC STN Files: ADISINSIGHT, BIOSIS, BIOTECHNO, CA, CAPLUS, CHEMCATS, EMBASE,  
PROUSDDR, TOXCENTER, USPAT2, USPATFULL

Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

56 REFERENCES IN FILE CA (1907 TO DATE)  
3 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
57 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
7.10	7.31

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 09:01:51 ON 21 SEP 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 21 Sep 2006 VOL 145 ISS 13

FILE LAST UPDATED: 20 Sep 2006 (20060920/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> l1

L2 57 L1

=> d l2 47-57 ti

L2 ANSWER 47 OF 57 CAPLUS COPYRIGHT 2006 ACS on STN

TI Inhibition of histone deacetylase as a treatment for cardiac hypertrophy

L2 ANSWER 48 OF 57 CAPLUS COPYRIGHT 2006 ACS on STN

TI Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase

L2 ANSWER 49 OF 57 CAPLUS COPYRIGHT 2006 ACS on STN

TI Preparation of N-acylaminoalkanehydroxamic acids as IL-6 production inhibitors

L2 ANSWER 50 OF 57 CAPLUS COPYRIGHT 2006 ACS on STN

TI Histone deacetylase inhibitors enhancing iodide or iodine uptake and uses in diagnosis and treatment of thyroid neoplasms

L2 ANSWER 51 OF 57 CAPLUS COPYRIGHT 2006 ACS on STN

TI Method of treating autoimmune diseases with histone hyperacetylating agent

L2 ANSWER 52 OF 57 CAPLUS COPYRIGHT 2006 ACS on STN

TI Chemical inducers for morphological reversion of oncogenically transformed NIH3T3 cells

L2 ANSWER 53 OF 57 CAPLUS COPYRIGHT 2006 ACS on STN

TI The novel anti-tumor agent oxamflatin differentially regulates urokinase and plasminogen activator inhibitor type 2 expression and inhibits urokinase-mediated proteolytic activity

L2 ANSWER 54 OF 57 CAPLUS COPYRIGHT 2006 ACS on STN

TI Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase

L2 ANSWER 55 OF 57 CAPLUS COPYRIGHT 2006 ACS on STN

TI Oxamflatin: a novel compound which reverses malignant phenotype to normal one via induction of JunD

L2 ANSWER 56 OF 57 CAPLUS COPYRIGHT 2006 ACS on STN

TI (2E)-5-[3-[(Phenylsulfonyl)amino]phenyl]-pent-2-en-4-ynohydroxamic Acid and Its Derivatives as Novel and Potent Inhibitors of ras Transformation

L2 ANSWER 57 OF 57 CAPLUS COPYRIGHT 2006 ACS on STN

TI Preparation of sulfonamidoaryl hydroxamic acids as inflammation and tumor inhibitors

=> d 12 57 ti fbib abs

L2 ANSWER 57 OF 57 CAPLUS COPYRIGHT 2006 ACS on STN

TI Preparation of sulfonamidoaryl hydroxamic acids as inflammation and tumor inhibitors

AN 1994:54333 CAPLUS

DN 120:54333

TI Preparation of sulfonamidoaryl hydroxamic acids as inflammation and tumor inhibitors

IN Ohtani, Mitsuaki; Arita, Hitoshi; Sugita, Kenji; Matsuura, Takaharu; Shirahase, Kazuhiro

PA Shionogi and Co., Ltd., Japan

SO PCT Int. Appl., 125 pp.  
CODEN: PIXXD2


DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9312075	A1	19930624	WO 1992-JP1593	19921207

W: JP, KR, US  
 RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE  
 JP 1991-350793 A 19911210  
 EP 570594 A1 19931124 EP 1992-924883 19921207  
 EP 570594 B1 19970730  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, PT, SE  
 JP 1991-350793 A 19911210  
 WO 1992-JP1593 W 19921207  
 AT 156116 E 19970815 AT 1992-924883 19921207  
 JP 1991-350793 A 19911210  
 ES 2107557 T3 19971201 ES 1992-924883 19921207  
 JP 1991-350793 A 19911210  
 JP 3342485 B2 20021111 JP 1993-510775 19921207  
 JP 1991-350793 A 19911210  
 WO 1992-JP1593 W 19921207  
 US 5534654 A 19960709 US 1993-98272 19930803  
 JP 1991-350793 A 19911210  
 WO 1992-JP1593 W 19921207  
 OS MARPAT 120:54333  
 GI



AB The title compds. R2ONR1COXA1YNR3BA2 (I) [A1 = (substituted) aromatic ring, aromatic heterocyclic ring; A2 = H, (substituted) aryl, aromatic heterocyclic ring; B = single bond, B1B2; B1 = CO, SO2; B2 = alkylene, alkenylene, etc.; X = (substituted) alkylene which may have O, S, N and may have unsatd. bond; Y = single bond, heteroatom, (substituted) alkylene which may contain heteroatom and may have unsatd. bond; X and N (which is linked to Y) may together form a moiety Q; R1 - R3 = H, (substituted) alkyl, aryl] were prepared I inhibit hemangioendothelial cell growth, the development of a lymphocyte adhesion factor, and ras gene-induced cell transformation and are useful as inflammation and tumor inhibitors. Condensation of carboxylic acid (E)-II (R = OH) with NH2OH.HCl in DMF containing N-hydroxysuccinimide, N,N-dicyclohexylcarbodiimide, and Et3N gave (E)-II (R = NHOH). Hydroxamic acid (E)-III in vitro exhibited MIC of 0.039  $\mu$ M against ras gene-induced cell transformation.

=> sodium (1)transport  
 1060363 SODIUM  
 35 SODIUMS  
 1060372 SODIUM  
 (SODIUM OR SODIUMS)  
 708922 TRANSPORT  
 5830 TRANSPORTS  
 711245 TRANSPORT  
 (TRANSPORT OR TRANSPORTS)

L3 43283 SODIUM (L)TRANSPORT

=> l2 and l3

L4 1 L2 AND L3

=> d l4 ti fbi abs

'FBI' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS ----- GI and AB  
ALL ----- BIB, AB, IND, RE  
APPS ----- AI, PRAI  
BIB ----- AN, plus Bibliographic Data and PI table (default)  
CAN ----- List of CA abstract numbers without answer numbers  
CBIB ----- AN, plus Compressed Bibliographic Data  
CLASS ----- IPC, NCL, ECLA, FTERM  
DALL ----- ALL, delimited (end of each field identified)  
DMAX ----- MAX, delimited for post-processing  
FAM ----- AN, PI and PRAI in table, plus Patent Family data  
FBIB ----- AN, BIB, plus Patent FAM  
IND ----- Indexing data  
IPC ----- International Patent Classifications  
MAX ----- ALL, plus Patent FAM, RE  
PATS ----- PI, SO  
SAM ----- CC, SX, TI, ST, IT  
SCAN ----- CC, SX, TI, ST, IT (random display, no answer numbers;  
SCAN must be entered on the same line as the DISPLAY,  
e.g., D SCAN or DISPLAY SCAN)  
STD ----- BIB, CLASS  
  
IABS ----- ABS, indented with text labels  
IALL ----- ALL, indented with text labels  
IBIB ----- BIB, indented with text labels  
IMAX ----- MAX, indented with text labels  
ISTD ----- STD, indented with text labels  
  
OBIB ----- AN, plus Bibliographic Data (original)  
OIBIB ----- OBIB, indented with text labels  
  
SBIB ----- BIB, no citations  
SIBIB ----- IBIB, no citations  
  
HIT ----- Fields containing hit terms  
HITIND ----- IC, ICA, ICI, NCL, CC and index field (ST and IT)  
containing hit terms  
HITRN ----- HIT RN and its text modification  
HITSTR ----- HIT RN, its text modification, its CA index name, and  
its structure diagram  
HITSEQ ----- HIT RN, its text modification, its CA index name, its  
structure diagram, plus NTE and SEQ fields  
FHITSTR ----- First HIT RN, its text modification, its CA index name, and  
its structure diagram  
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its  
structure diagram, plus NTE and SEQ fields  
KWIC ----- Hit term plus 20 words on either side  
OCC ----- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field codes. For a list of the display field codes, enter HELP DFIELDS at an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST; TI,IND; TI,SO. You may specify the format fields in any order and the information will be displayed in the same order as the format

specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC to view a specified Accession Number.

ENTER DISPLAY FORMAT (BIB):end

=> d 14 ti fbib abs

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN  
TI Histone deacetylase inhibitors enhancing iodide or iodine uptake and uses  
in diagnosis and treatment of thyroid neoplasms  
AN 2002:539823 CAPLUS  
DN 137:103874  
TI Histone deacetylase inhibitors enhancing iodide or iodine uptake and uses  
in diagnosis and treatment of thyroid neoplasms  
IN Fojo, Antonio Tito; Bates, Susan Elaine  
PA The Government of the United States of America, Department of Health &  
Human Services, USA  
SO PCT Int. Appl., 55 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002055688	A2	20020718	WO 2002-US714	20020108
	WO 2002055688	A3	20030410		
	WO 2002055688	C1	20030925		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2434269	AA	20020718	US 2001-260733P	P 20010110
				CA 2002-2434269	20020109
				US 2001-260733P	P 20010110
				WO 2002-US714	W 20020109
EP 1356053	A2	20031029	EP 2002-718823		20020109
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
				US 2001-260733P	P 20010110
				WO 2002-US714	W 20020108
JP 2005507231	T2	20050317	JP 2002-556736		20020109
			US 2001-260733P	P 20010110	
			WO 2002-US714	W 20020109	
US 2004132643	A1	20040708	US 2004-250320		20040102
			WO 2002-US714	W 20020108	

AB Disclosed herein are novel approaches to thyroid cancer therapy. These approaches include methods to enhance thyroid specific gene expression, for example methods to enhance expression of thyroglobulin and/or the Na<sup>+</sup>/I<sup>-</sup> symporter in thyroid cancer cells. Enhanced expression of thyroid-specific genes promotes cellular differentiation and reduces biol. aggressive behavior such as invasion and metastasis. In addition, enhanced expression of thyroglobulin and/or the Na<sup>+</sup>/I<sup>-</sup> symporter increases the ability of thyroid cancer cells to concentrate iodine or iodide, thereby making the cells more susceptible to radioactive iodine therapy. Also disclosed herein are methods for detecting thyroid neoplasms in a subject, by

administering a therapeutically effective amount of a histone deacetylase inhibitor, administering a detectable agent whose uptake or concentration in thyroid cells is increased by administration of the histone deacetylase inhibitor, and detecting the detectable agent.

=> d 14 it

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN

IT Thyroid gland, neoplasm

(anaplastic carcinoma; histone deacetylase inhibitors enhancing iodide or iodine uptake and uses in diagnosis and treatment of thyroid neoplasms)

IT Hydroxamic acids

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(bis-; histone deacetylase inhibitors enhancing iodide or iodine uptake and uses in diagnosis and treatment of thyroid neoplasms)

IT Diagnosis

Diagnosis

(cancer; histone deacetylase inhibitors enhancing iodide or iodine uptake and uses in diagnosis and treatment of thyroid neoplasms)

IT Thyroid gland

(carcinoma metastasis; histone deacetylase inhibitors enhancing iodide or iodine uptake and uses in diagnosis and treatment of thyroid neoplasms)

IT Thyroid gland, neoplasm

(carcinoma, insular and residual; histone deacetylase inhibitors enhancing iodide or iodine uptake and uses in diagnosis and treatment of thyroid neoplasms)

IT Hydroxamic acids

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(derivs.; histone deacetylase inhibitors enhancing iodide or iodine uptake and uses in diagnosis and treatment of thyroid neoplasms)

IT Thyroid gland, neoplasm

(follicular cell carcinoma; histone deacetylase inhibitors enhancing iodide or iodine uptake and uses in diagnosis and treatment of thyroid neoplasms)

IT Antitumor agents

Chemotherapy

Radiotherapy

Thyroid gland, neoplasm

(histone deacetylase inhibitors enhancing iodide or iodine uptake and uses in diagnosis and treatment of thyroid neoplasms)

IT Antisense oligonucleotides

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(histone deacetylase inhibitors enhancing iodide or iodine uptake and uses in diagnosis and treatment of thyroid neoplasms)

IT Thyroid gland, neoplasm

(papillary carcinoma; histone deacetylase inhibitors enhancing iodide or iodine uptake and uses in diagnosis and treatment of thyroid neoplasms)

IT Transport proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(sodium-iodine pump, enhancing expression of; histone deacetylase inhibitors enhancing iodide or iodine uptake and uses in diagnosis and treatment of thyroid neoplasms)

IT Carcinoma

(thyroid anaplastic; histone deacetylase inhibitors enhancing iodide or iodine uptake and uses in diagnosis and treatment of thyroid neoplasms)

IT Carcinoma

(thyroid follicular cell; histone deacetylase inhibitors enhancing iodide or iodine uptake and uses in diagnosis and treatment of thyroid neoplasms)



IT Carcinoma  
(thyroid papillary; histone deacetylase inhibitors enhancing iodide or iodine uptake and uses in diagnosis and treatment of thyroid neoplasms)

IT Carcinoma  
(thyroid, insular and residual; histone deacetylase inhibitors enhancing iodide or iodine uptake and uses in diagnosis and treatment of thyroid neoplasms)

IT Promoter (genetic element)  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(thyroid-specific, activation of; histone deacetylase inhibitors enhancing iodide or iodine uptake and uses in diagnosis and treatment of thyroid neoplasms)

IT Gene, animal  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(thyroid-specific, enhancing expression of; histone deacetylase inhibitors enhancing iodide or iodine uptake and uses in diagnosis and treatment of thyroid neoplasms)

IT Surgery  
Thyroid gland  
(thyroidectomy; histone deacetylase inhibitors enhancing iodide or iodine uptake and uses in diagnosis and treatment of thyroid neoplasms)

IT Biological transport  
(uptake; histone deacetylase inhibitors enhancing iodide or iodine uptake and uses in diagnosis and treatment of thyroid neoplasms)

IT 209783-80-2  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(MS 27-275; histone deacetylase inhibitors enhancing iodide or iodine uptake and uses in diagnosis and treatment of thyroid neoplasms)

IT 9076-57-7, Histone deacetylase 20461-54-5, Iodide, biological studies  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(histone deacetylase inhibitors enhancing iodide or iodine uptake and uses in diagnosis and treatment of thyroid neoplasms)

IT 7553-56-2, Iodine, biological studies  
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(histone deacetylase inhibitors enhancing iodide or iodine uptake and uses in diagnosis and treatment of thyroid neoplasms)

IT 14158-31-7, 125I, biological studies 15715-08-9, 123I, biological studies  
RL: DGN (Diagnostic use); BIOL (Biological study); USES (Uses)  
(histone deacetylase inhibitors enhancing iodide or iodine uptake and uses in diagnosis and treatment of thyroid neoplasms)

IT 10043-66-0, 131I, biological studies  
RL: DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(histone deacetylase inhibitors enhancing iodide or iodine uptake and uses in diagnosis and treatment of thyroid neoplasms)

IT 55-21-0, Benzamide 55-21-0D, Benzamide, derivs. 64-19-7D, Acetic acid, salts 107-92-6, Butyric acid, biological studies 107-92-6D, Butyric acid, salt 18992-11-5, Azelaic Bishydroxamic acid 25974-99-6, m-Carboxycinnamic acid 38937-66-5 42002-26-6 53342-16-8, Chlamydocin 58880-19-6, Trichostatin A 83209-65-8, HC-toxin 86402-37-1, WF-3161 128517-07-7, FR901228 133155-89-2, Trapoxin A 133155-90-5, Trapoxin B 139508-73-9, Depudecin 149647-78-9 151720-43-3, Oxamflatin 170720-16-8, Tan-1746 183506-66-3 183506-66-3D, analogs  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(histone deacetylase inhibitors enhancing iodide or iodine uptake and uses in diagnosis and treatment of thyroid neoplasms)

IT 14797-73-0, Perchlorate 23288-61-1  
RL: DGN (Diagnostic use); BIOL (Biological study); USES (Uses)  
(radiolabeled; histone deacetylase inhibitors enhancing iodide or iodine uptake and uses in diagnosis and treatment of thyroid neoplasms)

IT 442705-90-0 442705-91-1 442705-92-2

RL: PRP (Properties)  
(unclaimed nucleotide sequence; histone deacetylase inhibitors  
enhancing iodide or iodine uptake and uses in diagnosis and treatment  
of thyroid neoplasms)

=> 151720-43-3

REGISTRY INITIATED

Substance data SEARCH and crossover from CAS REGISTRY in progress...

Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

L6

57 L5

=> display hitstr 16 1-3

L6 ANSWER 1 OF 57 CAPLUS COPYRIGHT 2006 ACS on STN

IT INDEXING IN PROGRESS


IT 151720-43-3, Oxamflatin

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(HDAC inhibitor; HDAC inhibitors that promote BRM expression, methods  
for their identification, and their use in cancer treatment)

RN 151720-43-3 CAPLUS

CN 2-Penten-4-ynamide, N-hydroxy-5-[3-[(phenylsulfonyl)amino]phenyl]-, (2E)-  
(9CI) (CA INDEX NAME)

Double bond geometry as shown.



L6 ANSWER 2 OF 57 CAPLUS COPYRIGHT 2006 ACS on STN


IT 151720-43-3, Oxamflatin

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU  
(Therapeutic use); BIOL (Biological study); USES (Uses)  
(pharmaceutical composition for enhancing therapeutic effects of  
radiotherapy and chemotherapy on tumor)

RN 151720-43-3 CAPLUS


CN 2-Penten-4-ynamide, N-hydroxy-5-[3-[(phenylsulfonyl)amino]phenyl]-, (2E)-  
(9CI) (CA INDEX NAME)

Double bond geometry as shown.



L6 ANSWER 3 OF 57 CAPLUS COPYRIGHT 2006 ACS on STN  
 IT 151720-43-3, Oxamflatin  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (biol. response modifier and  $\beta$ -cell growth factor for restoring  
 $\beta$ -cell mass and function)  
 RN 151720-43-3 CAPLUS  
 CN 2-Penten-4-ynamide, N-hydroxy-5-[3-[(phenylsulfonyl)amino]phenyl]-, (2E)-  
 (9CI) (CA INDEX NAME)

Double bond geometry as shown.



=> logoff hold

COST IN U.S. DOLLARS

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

CA SUBSCRIBER PRICE

SINCE FILE	TOTAL
ENTRY	SESSION
9.52	41.19

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-1.50

SESSION WILL BE HELD FOR 60 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 09:16:08 ON 21 SEP 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:

\* \* \* \* \* RECONNECTED TO STN INTERNATIONAL \* \* \* \* \*  
SESSION RESUMED IN FILE 'CAPLUS' AT 09:39:39 ON 21 SEP 2006  
FILE 'CAPLUS' ENTERED AT 09:39:39 ON 21 SEP 2006  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	9.52	41.19
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-1.50

=> d his

(FILE 'HOME' ENTERED AT 09:00:46 ON 21 SEP 2006)

FILE 'REGISTRY' ENTERED AT 09:01:11 ON 21 SEP 2006  
E OXAMFLATIN/CN

L1 1 E3

FILE 'CAPLUS' ENTERED AT 09:01:51 ON 21 SEP 2006

L2 57 L1  
L3 43283 SODIUM (L)TRANSPORT  
L4 1 L2 AND L3  
S 151720-43-3/REG#

FILE 'REGISTRY' ENTERED AT 09:15:23 ON 21 SEP 2006

L5 1 S 151720-43-3/RN

FILE 'CAPLUS' ENTERED AT 09:15:23 ON 21 SEP 2006

L6 57 S L5

=> lung

186355 LUNG  
43168 LUNGS  
L7 200642 LUNG  
(LUNG OR LUNGS)

=> 16 and 17

L8 10 L6 AND L7

=> d 18 1-10 ti

L8 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN  
TI Use of thioredoxin measurements for diagnostics and treatments

L8 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN  
TI Use of thioredoxin measurements for diagnostics and treatments

L8 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN  
TI Method using histone deacetylase inhibitors for increasing therapeutic gain in radiotherapy and chemotherapy

L8 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN  
TI Formulation comprising histone deacetylase inhibitor exhibiting biphasic release

L8 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN  
TI Methods of NAD+-dependent deacetylase inhibitors

L8 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN  
 TI Combination methods of treating cancer

L8 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN  
 TI The Epigenome as a Target for Cancer Chemoprevention

L8 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN  
 TI Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and Alzheimer's disease

L8 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN  
 TI Method of treating TRX mediated diseases by administering histone deacetylase inhibitors

L8 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN  
 TI Preparation of N-acylaminoalkanehydroxamic acids as IL-6 production inhibitors

=> d 18 1-10 ti fbib abs

L8 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN  
 TI Use of thioredoxin measurements for diagnostics and treatments  
 AN 2005:1355554 CAPLUS  
 DN 144:81158  
 TI Use of thioredoxin measurements for diagnostics and treatments  
 IN Marks, Paul A.; Ungerstedt, Johanna  
 PA USA  
 SO U.S. Pat. Appl. Publ., 39 pp., Cont.-in-part of U.S. Ser. No. 369,094.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005288227	A1	20051229	US 2005-144301	20050603
				US 2002-357383P	P 20020215
				US 2003-369094	A2 20030214
				US 2004-577089P	P 20040604
	US 2003235588	A1	20031225	US 2003-369094	20030214
				US 2002-357383P	P 20020215
	US 2006009526	A1	20060112	US 2005-223405	20050909
				US 2002-357383P	P 20020215
				US 2003-369094	B1 20030214
	US 2006009527	A1	20060112	US 2005-223547	20050909
				US 2002-357383P	P 20020215
				US 2003-369094	B1 20030214

PATENT FAMILY INFORMATION:

FAN 2003:678618

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003070188	A2	20030828	WO 2003-US4924	20030214
	WO 2003070188	A3	20040219		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF,				

BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 2476434	AA	20030828	US 2002-357383P	P 20020215
			CA 2003-2476434	20030214
			US 2002-357383P	P 20020215
AU 2003219803	A1	20030909	WO 2003-US4924	W 20030214
			AU 2003-219803	20030214
			US 2002-357383P	P 20020215
			WO 2003-US4924	W 20030214
EP 1482962	A2	20041208	EP 2003-716078	20030214
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
			US 2002-357383P	P 20020215
			WO 2003-US4924	W 20030214
JP 2005525345	T2	20050825	JP 2003-569148	20030214
			US 2002-357383P	P 20020215
			WO 2003-US4924	W 20030214
AU 2005227400	A1	20051117	AU 2005-227400	20051028
			AU 2003-219803	A3 20030214
			WO 2003-US4924	W 20030214
FAN 2005:1313861				
PATENT NO. KIND DATE APPLICATION NO. DATE				
PI WO 2005117930	A2	20051215	WO 2005-US19523	20050603
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004-577089P P 20040604				
AB	The invention relates to methods for monitoring patient response to histone deacetylase inhibitors (e.g., suberoylanilide hydroxamic acid (SAHA)) or other therapeutic agents by measuring the level of thioredoxin in body fluids, tissues, and/or cells, such as peripheral blood mononuclear cells, plasma, or serum. The invention also relates to methods of monitoring and/or assisting with the diagnosis of a wide variety of thioredoxin-related diseases and conditions, such as inflammatory diseases, allergic diseases, autoimmune diseases, diseases associated with oxidative stress or diseases characterized by cellular hyperproliferation.			
L8	ANSWER 2 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN			
TI	Use of thioredoxin measurements for diagnostics and treatments			
AN	2005:1313861 CAPLUS			
DN	144:45450			
TI	Use of thioredoxin measurements for diagnostics and treatments			
IN	Marks, Paul A.; Ungerstedt, Johanna			
PA	Sloan-Kettering Institute for Cancer Research, USA			
SO	PCT Int. Appl., 81 pp. CODEN: PIXXD2			
DT	Patent			
LA	English			
FAN.CNT 3				
PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005117930	A2	20051215	WO 2005-US19523	20050603
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2004-577089P P 20040604

PATENT FAMILY INFORMATION:

FAN 2003:678618

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003070188	A2	20030828	WO 2003-US4924	20030214
	WO 2003070188	A3	20040219		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2476434	AA	20030828	US 2002-357383P	P 20020215
				CA 2003-2476434	20030214
				US 2002-357383P	P 20020215
				WO 2003-US4924	W 20030214
	AU 2003219803	A1	20030909	AU 2003-219803	20030214
				US 2002-357383P	P 20020215
				WO 2003-US4924	W 20030214
	EP 1482962	A2	20041208	EP 2003-716078	20030214
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
				US 2002-357383P	P 20020215
				WO 2003-US4924	W 20030214
	JP 2005525345	T2	20050825	JP 2003-569148	20030214
				US 2002-357383P	P 20020215
				WO 2003-US4924	W 20030214
	AU 2005227400	A1	20051117	AU 2005-227400	20051028
				AU 2003-219803	A3 20030214
				WO 2003-US4924	W 20030214

FAN 2005:1355554

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005288227	A1	20051229	US 2005-144301	20050603
				US 2002-357383P	P 20020215
				US 2003-369094	A2 20030214
				US 2004-577089P	P 20040604
	US 2003235588	A1	20031225	US 2003-369094	20030214
				US 2002-357383P	P 20020215
	US 2006009526	A1	20060112	US 2005-223405	20050909
				US 2002-357383P	P 20020215
				US 2003-369094	B1 20030214
	US 2006009527	A1	20060112	US 2005-223547	20050909
				US 2002-357383P	P 20020215
				US 2003-369094	B1 20030214

AB The invention relates to methods for monitoring patient response to histone deacetylase inhibitors (e.g., suberoylanilide hydroxamic acid

(SAHA)) or other therapeutic agents by measuring the level of thioredoxin in body fluids, tissues, and/or cells, such as peripheral blood mononuclear cells, plasma, or serum. The invention also relates to methods of monitoring and/or assisting with the diagnosis of a wide variety of thioredoxin-related diseases and conditions, such as inflammatory diseases, allergic diseases, autoimmune diseases, diseases associated with oxidative stress or diseases characterized by cellular hyperproliferation.

L8 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN  
 TI Method using histone deacetylase inhibitors for increasing therapeutic gain in radiotherapy and chemotherapy  
 AN 2005:1292833 CAPLUS  
 DN 144:32206  
 TI Method using histone deacetylase inhibitors for increasing therapeutic gain in radiotherapy and chemotherapy  
 IN Chung, Yih-Lin  
 PA Taiwan  
 SO U.S. Pat. Appl. Publ., 37 pp., Cont.-in-part of U.S. Ser. No. 205,738. CODEN: USXXCO  
 DT Patent  
 LA English  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005272644	A1	20051208	US 2004-798119	20040311
				US 2002-205738	A2 20020725
	US 2004018958	A1	20040129	US 2002-205738	20020725
	US 6809118	B2	20041026		

PATENT FAMILY INFORMATION:

FAN 2004:80330

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004018958	A1	20040129	US 2002-205738	20020725
	US 6809118	B2	20041026		
	EP 1574213	A1	20050914	EP 2004-5807	20040311
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK			US 2002-205738	A 20020725
	US 2005272644	A1	20051208	US 2004-798119	20040311
				US 2002-205738	A2 20020725
	JP 2005281150	A2	20051013	JP 2004-93861	20040326
				US 2002-205738	A 20020725

AB The invention provides compns. and methods for increasing therapeutic gain in radiotherapy and chemotherapy for proliferating malignant or nonmalignant disease to produce high probability of tumor control with low frequency of sequelae of therapy by administering a therapeutically effective amount of a histone deacetylase inhibitor. The compds. are capable of simultaneously stimulating epithelial regrowth, inhibiting fibroblast proliferation, decreasing collagen deposits, suppressing fibrogenic growth factor, subsiding proinflammatory cytokine, and modulating expression of cell cycle genes, tumor suppressors and oncogenes, and are useful for increasing the therapeutic gain in radiotherapy and chemotherapy, which results in decrease of skin swelling and inflammation, promotion of epithelial healing in mucosa and dermis, decrease of xerostomia, prevention/reduction of severity of plantar-palmar syndrome, prevention of tissue fibrosis, ulceration, necrosis and tumorigenesis, and increase of tumor growth inhibition and tumor therapy effectiveness.

L8 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN  
 TI Formulation comprising histone deacetylase inhibitor exhibiting biphasic release



AN 2005:1168848 CAPLUS  
 DN 143:446691  
 TI Formulation comprising histone deacetylase inhibitor exhibiting biphasic release  
 IN Franke, Hanshermann; Lennartz, Peter; Maurer, Alexander, B.; Hentsch, Bernd; Hoevelmann, Sascha; Martin, Elke  
 PA G2M Cancer Drugs A.-G., Germany; Desitin Arzneimittel G.m.b.H.  
 SO Eur. Pat. Appl., 29 pp.  
 CODEN: EPXXDW  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1591109	A1	20051102	EP 2004-10333	20040430
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	WO 2005105055	A1	20051110	WO 2005-EP4739	20050502
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				EP 2004-10333	A 20040430

OS MARPAT 143:446691  
 AB The present invention relates to an orally available galenics formulation of Valproic Acid or derivs. thereof exhibiting a specific bi-phasic pharmacokinetic profile optimized for maximum inhibition of histone deacetylases in a therapeutic setting. This specific galenics formulation is designed for the treatment of malignant diseases and diseases associated with hypoacetylation of histones or in which induction of hyperacetylation has a beneficial effect, e.g., by induction of differentiation and/or apoptosis. Due to the bi-phasic release pattern the resulting pharmacokinetic profile is able to inhibit HDAC target enzymes most efficiently and to subsequently induce histone hyperacetylation in a rapid as well as a long-lasting fashion. This profile secures the efficient modulation of a desired target gene expression profile which contributes to the therapeutic benefit.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN  
 TI Methods of NAD+-dependent deacetylase inhibitors  
 AN 2005:523233 CAPLUS  
 DN 143:53553  
 TI Methods of NAD+-dependent deacetylase inhibitors  
 IN Zhang, Jie; Xu, Weizheng  
 PA Guilford Pharmaceuticals Inc., USA  
 SO PCT Int. Appl., 49 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005053609	A2	20050616	WO 2004-US39220	20041123

WO 2005053609

A3

20050901

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW




RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003-525303P

P 20031126

OS MARPAT 143:53553

GI



AB The present invention relates to methods of treating cancer, cardiovascular disorders, and neurol. disorders using NAD<sup>+</sup>-dependent deacetylase Sir2 inhibitors. The present invention also relates to a method comprising administering an effective amount of a NAD<sup>+</sup>-dependent deacetylase inhibitor and a Type I or Type II histone deacetylase inhibitor to treat cancer. The present invention involves a method of an effective amount of a NAD<sup>+</sup>-dependent deacetylase inhibitor to treat cancer wherein said SIR2 inhibitor can be a compound of formula I, wherein X is O, N, S, P, C=O; A is a bond, H, CH<sub>2</sub>, CHR<sub>8</sub>, -CH<sub>2</sub>-NH-, -CHR<sub>8</sub>-NH-, -CH<sub>2</sub>-NR<sub>8</sub>-, -(CH<sub>2</sub>)<sub>2</sub>-, -CH<sub>2</sub>-CHR<sub>8</sub>-; B is C, N, S, C-A, N-A, S-A; and R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub>, R<sub>8</sub>, R<sub>9</sub> can be an optionally substituted H, F, Cl, Br, I, amino, hydroxy, -N-N, -CO-N-N, halogen-substituted amino, -O-alkyl, -O-aryl, or an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, etc. The NAD<sup>+</sup>-dependent deacetylase inhibitor can also be formula II wherein X is O, N, S, P; A is O, S, S=O, SO<sub>2</sub>, CH<sub>2</sub>, CHR<sub>9</sub>, -CH<sub>2</sub>-NH-, -CHR<sub>9</sub>-NH-, -CH<sub>2</sub>-NR<sub>9</sub>-, -(CH<sub>2</sub>)<sub>2</sub>-, -CH<sub>2</sub>-CHR<sub>9</sub>-; and R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub>, R<sub>8</sub>, R<sub>9</sub> can be an optionally substituted H, F, Cl, Br, I, amino, hydroxy, -N-N, -CO-N-N, halogen-substituted amino, -O-alkyl, -O-aryl, or an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, etc. In addition, the

NAD+-dependent deacetylase inhibitor can be formula III wherein X is O, N, S, P; and R1, R2, R3, R4, R5, R6 is an optionally substituted H, F, Cl, Br, I, amino, hydroxy, -N-N, -CO-N-N, halogen-substituted amino, -O-alkyl, -O-aryl, or an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, etc.

L8 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN  
 TI Combination methods of treating cancer  
 AN 2005:232565 CAPLUS  
 DN 142:309871  
 TI Combination methods of treating cancer  
 IN Bacopoulos, Nicholas G.; Chiao, Judy H.; Marks, Paul A.; Miller, Thomas A.; Paradise, Carolyn M.; Richon, Victoria M.; Rifkind, Richard A.  
 PA Aton Pharma, Inc., USA; Sloan-Kettering Institute for Cancer Research  
 SO PCT Int. Appl., 134 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005023179	A2	20050317	WO 2004-US26161	20040812
	WO 2005023179	A3	20050616		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2004270150	A2	20050317	US 2003-498803P	P 20030829
	AU 2004270150	A1	20050317	AU 2004-270150	20040812
				US 2003-498803P	P 20030829
				WO 2004-US26161	W 20040812
	CA 2535889	AA	20050317	CA 2004-2535889	20040812
				US 2003-498803P	P 20030829
				WO 2004-US26161	W 20040812
	EP 1667680	A2	20060614	EP 2004-780925	20040812
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			
				US 2003-498803P	P 20030829
				WO 2004-US26161	W 20040812

OS MARPAT 142:309871  
 AB The present invention relates to a method of treating cancer in a subject in need thereof, by administering to a subject in need thereof a first amount of a histone deacetylase (HDAC) inhibitor or a pharmaceutically acceptable salt or hydrate thereof, in a first treatment procedure, and a second amount of an anti-cancer agent in a second treatment procedure. The first and second amts. together comprise a therapeutically effective amount. The effect of the HDAC inhibitor and the anti-cancer agent may be additive or synergistic.

L8 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN  
 TI The Epigenome as a Target for Cancer Chemoprevention  
 AN 2003:983640 CAPLUS  
 DN 141:16551  
 TI The Epigenome as a Target for Cancer Chemoprevention  
 AU Kopelovich, Levy; Crowell, James A.; Fay, Judith R.

CS National Cancer Institute, Chemopreventive Agent Development Research Group, National Institutes of Health, Bethesda, MD, USA  
 SO Journal of the National Cancer Institute (2003), 95(23), 1747-1757  
 CODEN: JNCIEQ; ISSN: 0027-8874  
 PB Oxford University Press  
 DT Journal; General Review  
 LA English  
 AB A review. Epigenetic events, a key driving force in the development of cancer, are alterations in gene expression without changes in the DNA coding sequence that are heritable through cell division. Such changes occur throughout all stages of tumorigenesis, including the early phases, and are increasingly recognized as major mechanisms involved in silencing tumor suppressor genes. Epigenetic changes can be reversed by the use of small mols. and, thus, such changes are promising targets for cancer chemopreventive drug development. This review examines the basis for targeting the epigenome as a prevention strategy, focusing on understanding the epigenetic changes that occur before the development of frank malignancy, when chemopreventive intervention will have the maximal impact.

RE.CNT 121 THERE ARE 121 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN  
 TI Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and Alzheimer's disease  
 AN 2003:796863 CAPLUS  
 DN 139:286376  
 TI Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and Alzheimer's disease  
 IN Dangond, Fernando  
 PA Brigham and Women's Hospital, Inc., USA  
 SO PCT Int. Appl., 57 pp.  
 CODEN: PIXXD2

DT Patent  
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003083067	A2	20031009	WO 2003-US9273	20030327
	WO 2003083067	C1	20040819		
	WO 2003083067	A3	20050324		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2002-368228P	P 20020328
				US 2002-404664P	P 20020820
AU	2003226014	A1	20031013	AU 2003-226014	20030327
				US 2002-368228P	P 20020328
				US 2002-404664P	P 20020820
				WO 2003-US9273	W 20030327
US	2004077591	A1	20040422	US 2003-401274	20030327
				US 2002-368228P	P 20020328
				US 2002-404664P	P 20020820

AB The present invention provide therapies for Alzheimer's disease (AD), multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS). The method relies on the use of an HDAC inhibitor, alone or in combination

with other drugs, to prevent or treat AD, MS or ALS. Also provided are methods of screening for addnl. HDAC inhibitors with particular efficacy against these disease states. Modulation of expression of genes, involved in neuroprotection and immune regulation, by HDAC inhibitors were demonstrated.

L8 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN  
 TI Method of treating TRX mediated diseases by administering histone deacetylase inhibitors  
 AN 2003:678618 CAPLUS  
 DN 139:207775  
 TI Method of treating TRX mediated diseases by administering histone deacetylase inhibitors  
 IN Richon, Victoria M.; Marks, Paul A.; Rifkind, Richard A.; Butler, Lisa M.  
 PA Sloan-Kettering Institute for Cancer Research, USA  
 SO PCT Int. Appl., 97 pp..  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2003070188	A2	20030828	WO 2003-US4924	20030214	
	WO 2003070188	A3	20040219			
	W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW		
	RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
	CA 2476434	AA	20030828	US 2002-357383P	P 20020215	
				CA 2003-2476434	20030214	
				US 2002-357383P	P 20020215	
				WO 2003-US4924	W 20030214	
	AU 2003219803	A1	20030909	AU 2003-219803	20030214	
				US 2002-357383P	P 20020215	
				WO 2003-US4924	W 20030214	
	EP 1482962	A2	20041208	EP 2003-716078	20030214	
	R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK		
				US 2002-357383P	P 20020215	
				WO 2003-US4924	W 20030214	
	JP 2005525345	T2	20050825	JP 2003-569148	20030214	
				US 2002-357383P	P 20020215	
				WO 2003-US4924	W 20030214	
	AU 2005227400	A1	20051117	AU 2005-227400	20051028	
				AU 2003-219803	A3 20030214	
				WO 2003-US4924	W 20030214	

PATENT FAMILY INFORMATION:

FAN 2005:1313861

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2005117930	A2	20051215	WO 2005-US19523	20050603	
	W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,		

ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,  
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
 EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,  
 RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,  
 MR, NE, SN, TD, TG

US 2004-577089P P 20040604

FAN 2005:1355554

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005288227	A1	20051229	US 2005-144301	20050603
			US 2002-357383P	P 20020215
			US 2003-369094	A2 20030214
			US 2004-577089P	P 20040604
US 2003235588	A1	20031225	US 2003-369094	20030214
			US 2002-357383P	P 20020215
US 2006009526	A1	20060112	US 2005-223405	20050909
			US 2002-357383P	P 20020215
			US 2003-369094	B1 20030214
US 2006009527	A1	20060112	US 2005-223547	20050909
			US 2002-357383P	P 20020215
			US 2003-369094	B1 20030214

OS MARPAT 139:207775

AB The invention provides a novel method for treating and/or preventing thioredoxin (TRX)-mediated diseases and conditions, by administering to a subject in need of such treatment a therapeutically effective amount of a histone deacetylase (HDAC) inhibitor or a pharmaceutically acceptable salt or hydrate thereof. The HDAC inhibitor can alter the expression of a thioredoxin-binding-protein (e.g. TBP-2), which in turn can lead to an altered TRX/thioredoxin-binding-protein cellular binding interaction, resulting in an increase or decrease in the level or activity of cellular TRX, for example the expression level or reducing activity of TRX. Thus the invention relates to the use of HDAC inhibitors in a method of preventing and/or treating a wide variety of thioredoxin (TRX)-mediated diseases and conditions, such as inflammatory diseases, allergic diseases, autoimmune diseases, diseases associated with oxidative stress or diseases characterized by cellular hyperproliferation.

L8 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN

TI Preparation of N-acylaminoalkanehydroxamic acids as IL-6 production inhibitors

AN 2002:736103 CAPLUS

DN 137:247516

TI Preparation of N-acylaminoalkanehydroxamic acids as IL-6 production inhibitors

IN Naka, Masao; Takahashi, Kanji

PA Ono Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 194 pp.

CODEN: PIXXD2

DT Patent


LA Japanese

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002074298	A1	20020926	WO 2002-JP2681	20020320
W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW	
RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,	

BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
			JP 2001-81302	A 20010321
US 2005119305	A1	20050602	US 2003-472160	20030922
			JP 2001-81302	A 20010321
			WO 2002-JP2681	W 20020320

OS MARPAT 137:247516  
GI



AB Interleukin 6 (IL-6) production inhibitors containing as the active ingredient hydroxamic acid derivs. (I) or equivalent thereto, non-toxic salts thereof or prodrugs of the same [R1 = C1-8 alkyl, C2-8 alkenyl or alkynyl, halo, NO2, cyano, CF3, CF3O, OR2, SR2, NR3R4, keto, cyclic group, COR5, SO2R10, SOR10, etc. (wherein R2-R4 = H, C1-8 alkyl, C2-9 acyl, cyclic group; R5 = HO, C1-8 alkyl or alkoxy, optionally substituted NH2, cyclic group; R10 = C1-8 alkyl, cyclic group); A = single bond, C3-15 mono-, di-, or tricyclic carbocyclic ring, 5- to 18-membered mono-, di-, or tricyclic heterocyclic ring containing 1-4 N, 1-2 O and/or 1-2 S atoms; E = a single bond, C1-8 alkylene, C2-8 alkenylene or alkynylene, O, SO2NH, NHSO2, CONH, NHCO, etc.; B = s single bond, C5-15 mono-, di-, or tricyclic carbocyclic ring; 5- to 18-membered mono-, di-, or tricyclic heterocyclic ring containing 1-4 N, 1-2 O and/or 1-2 S atoms; R8 = C1-8 alkyl or alkoxy, halo, NO2, cyano, CF3, CF3O, HO, C1-8 hydroxyalkyl; when E is a single bond, R1 and R8 together represents a C1-4 alkylene; n = an integer of 1-5; G = a single bond, (un)substituted NHCO or CONH, O, S, SO, SO2, (un)substituted SO2NH, CO, etc.; L = C1-8 alkylene, C2-8 alkenylene or alkynylene, C2-8 alkenylene-C2-8 alkynylene, C2-8 alkylene-C2-8 alkenylene, etc.; Q = (un)substituted CONHOH, oxiranylcarbonyl, (un)substituted SH, P(O)(OH)2 or its C1-4 alkyl ester; some proviso are given] are claimed. Because of having an IL-6 production inhibitory activity, the compds. of the general formula I are useful as preventives and/or remedies for various inflammatory diseases, sepsis, multiple myeloma, plasmacytoid leukemia, osteoporosis, cachexia, psoriasis, nephritis, kidney cell cancer, Kaposi's sarcoma, rheumatoid arthritis, hypergamma globulinemia, Castleman's disease, intra-atrial myxoma, diabetes, autoimmune diseases, hepatitis, colitis, graft-vs.-host disease, infections, endometriosis and solid cancer. The solid cancer include brain tumor, head and neck cancer, thyroid gland cancer, esophageal cancer, stomach cancer, colorectal cancer (colon cancer and rectum cancer), liver cancer, gallbladder cancer, bile duct cancer (cholangioma), pancreatic cancer, lung cancer, breast cancer, cervical cancer, uterine cancer, ovarian cancer, prostatic cancer, testicular tumor, bladder cancer, renal pelvis tumor, ureteral tumor, adrenal cancer (hypernephroma), neuroma, glioma, bone tumor, rhabdomyosarcoma, osteosarcoma, soft tissue tumor, eosinophilic granuloma, malignant melanoma, skin cancer, Wilms's tumor, etc. Thus, to a solution of 2.24 g 6-[(4-phenylbenzoyl)amino]hexanoic acid in 42 mL DMF were successively added 1-hydroxybenzotriazole hydrate 1.65, Et3N 2.91, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride 2.07, and N-(1-methyl-1-methoxyethoxy)amine 1.14 g and stirred at room temperature for 4

h

to give 1.79 g N-(1-methyl-1-methoxyethoxy)-6-[(4-phenylbenzoyl)amino]hexanamide which (1.78 g) was dissolved in 4.5 mL MeOH and stirred with 4.5 mL 2 N aqueous HCl at room temperature to give N-hydroxy-6-[(4-phenylbenzoyl)amino]hexanamide (II). II in vitro inhibited the production of IL-6 in human lung epithelial cell A549

with IC50 of 0.18  $\mu$ M. A tablet and an ampule formulation containing II were prepared  
RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> hydroxam?

L9 7 HYDOXAM?

=> hydroxam?

L10 10111 HYDROXAM?

=> d his

(FILE 'HOME' ENTERED AT 09:00:46 ON 21 SEP 2006)

FILE 'REGISTRY' ENTERED AT 09:01:11 ON 21 SEP 2006  
E OXAMFLATIN/CN

L1 1 E3

FILE 'CAPLUS' ENTERED AT 09:01:51 ON 21 SEP 2006

L2 57 L1

L3 43283 SODIUM (L)TRANSPORT

L4 1 L2 AND L3

S 151720-43-3/REG#

FILE 'REGISTRY' ENTERED AT 09:15:23 ON 21 SEP 2006

L5 1 S 151720-43-3/RN

FILE 'CAPLUS' ENTERED AT 09:15:23 ON 21 SEP 2006

L6 57 S L5

L7 200642 LUNG

L8 10 L6 AND L7

L9 7 HYDOXAM?

L10 10111 HYDROXAM?

=> 13(1)110

L11 9 L3(L)L10

=> d l11 1-9 ti

L11 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

TI Detection of an FeL2 Complex of Ferrioxamine B and Determination of Its Stability Constant in Aqueous Micellar SDS

L11 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

TI A preparation of unsaturated hydroxamic acid derivatives useful as histone deacetylase inhibitors

L11 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

TI Glutamate-induced inhibition of D-aspartate uptake in mueller glia from the retina

L11 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

TI Characterization of cystine uptake in cultured astrocytes

L11 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

TI Regulation of high-affinity glutamate uptake activity in Bergmann glia cells by glutamate

L11 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

TI Accumulation of extracellular glutamate by inhibition of its uptake is not sufficient for inducing neuronal damage: an in vivo microdialysis study



L11 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN  
 TI Comparative analysis of sodium-dependent L-glutamate transport of  
 synaptosomal and astroglial membrane vesicles from mouse cortex

L11 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN  
 TI Chiral linear hydroxamates as biomimetic analogs of ferrioxamine and  
 coprogen and their use in probing siderophore-receptor specificity in  
 bacteria and fungi

L11 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN  
 TI Iron-dependent production of hydroxamate by sodium-dependent Azotobacter  
 chroococcum

=> d l11 2 ti fbib abs

L11 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN  
 TI A preparation of unsaturated hydroxamic acid derivatives useful as histone  
 deacetylase inhibitors  
 AN 2004:453179 CAPLUS  
 DN 141:23197  
 TI A preparation of unsaturated hydroxamic acid derivatives useful as histone  
 deacetylase inhibitors  
 IN Wiech, Norbert L.; Lan-Hargest, Hsuan-yin  
 PA Circagen Pharmaceutical, USA; Beacon Laboratories  
 SO PCT Int. Appl., 27 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 5

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004046104	A2	20040603	WO 2003-US36981	20031119
WO 2004046104	A3	20040805		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2506504	AA	20040603	US 2002-427567P	P 20021120
			CA 2003-2506504	20031119
			US 2002-427567P	P 20021120
			WO 2003-US36981	W 20031119
AU 2003291097	A1	20040615	AU 2003-291097	20031119
			US 2002-427567P	P 20021120
			WO 2003-US36981	W 20031119
EP 1567142	A2	20050831	EP 2003-783686	20031119
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
			US 2002-427567P	P 20021120
			WO 2003-US36981	W 20031119
JP 2006508986	T2	20060316	JP 2004-553939	20031119
			US 2002-427567P	P 20021120
			WO 2003-US36981	W 20031119

PATENT FAMILY INFORMATION:

FAN 2002:754352


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

PI	WO 2002076941	A2	20021003	WO 2002-US8836	20020325
	WO 2002076941	A3	20040212		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2001-812940	A1 20010327
				US 2001-812944	A1 20010327
				US 2001-812945	A1 20010327
				US 2001-25947	A1 20011226
	US 2002143196	A1	20021003	US 2001-812944	20010327
	US 6495719	B2	20021217		
	US 2002143052	A1	20021003	US 2001-812945	20010327
	US 2002143037	A1	20021003	US 2001-25947	20011226
				US 2001-812940	B1 20010327
	CA 2442366	AA	20021003	CA 2002-2442366	20020325
				US 2001-812940	A 20010327
				US 2001-812944	A 20010327
				US 2001-812945	A 20010327
				US 2001-25947	A 20011226
				WO 2002-US8836	W 20020325
	AU 2002250401	A1	20021008	AU 2002-250401	20020325
				US 2001-812940	A 20010327
				US 2001-812944	A 20010327
				US 2001-812945	A 20010327
				US 2001-25947	A 20011226
				WO 2002-US8836	W 20020325
	EP 1408946	A2	20040421	EP 2002-719311	20020325
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
				US 2001-812940	A 20010327
				US 2001-812944	A 20010327
				US 2001-812945	A 20010327
				US 2001-25947	A 20011226
				WO 2002-US8836	W 20020325
FAN	2002:755220				
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002143052	A1	20021003	US 2001-812945	20010327
	CA 2442366	AA	20021003	CA 2002-2442366	20020325
				US 2001-812940	A 20010327
				US 2001-812944	A 20010327
				US 2001-812945	A 20010327
				US 2001-25947	A 20011226
				WO 2002-US8836	W 20020325
	WO 2002076941	A2	20021003	WO 2002-US8836	20020325
	WO 2002076941	A3	20040212		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,				

GN, GQ, GW, ML, MR, NE, SN, TD, TG

			US 2001-812940	A1	20010327
			US 2001-812944	A1	20010327
			US 2001-812945	A1	20010327
			US 2001-25947	A1	20011226
AU 2002250401	A1	20021008	AU 2002-250401		20020325
			US 2001-812940	A	20010327
			US 2001-812944	A	20010327
			US 2001-812945	A	20010327
			US 2001-25947	A	20011226
			WO 2002-US8836	W	20020325
EP 1408946	A2	20040421	EP 2002-719311		20020325
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
			US 2001-812940	A	20010327
			US 2001-812944	A	20010327
			US 2001-812945	A	20010327
			US 2001-25947	A	20011226
			WO 2002-US8836	W	20020325
US 2003125306	A1	20030703	US 2002-318225		20021213
			US 2001-812945	A3	20010327
US 2005107348	A1	20050519	US 2004-19303		20041223
			US 2001-812945	A3	20010327
US 2005171208	A1	20050804	US 2005-59377		20050217
			US 2001-812945	A3	20010327
FAN 2002:755255					
PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
-----	-----	-----	-----		-----
PI US 2002143196	A1	20021003	US 2001-812944		20010327
US 6495719	B2	20021217			
CA 2442366	AA	20021003	CA 2002-2442366		20020325
			US 2001-812940	A	20010327
			US 2001-812944	A	20010327
			US 2001-812945	A	20010327
			US 2001-25947	A	20011226
			WO 2002-US8836	W	20020325
WO 2002076941	A2	20021003	WO 2002-US8836		20020325
WO 2002076941	A3	20040212			
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
			US 2001-812940	A1	20010327
			US 2001-812944	A1	20010327
			US 2001-812945	A1	20010327
			US 2001-25947	A1	20011226
AU 2002250401	A1	20021008	AU 2002-250401		20020325
			US 2001-812940	A	20010327
			US 2001-812944	A	20010327
			US 2001-812945	A	20010327
			US 2001-25947	A	20011226
			WO 2002-US8836	W	20020325
EP 1408946	A2	20040421	EP 2002-719311		20020325
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
			US 2001-812940	A	20010327
			US 2001-812944	A	20010327

				US 2001-812945	A 20010327
				US 2001-25947	A 20011226
				WO 2002-US8836	W 20020325
	US 2003083521	A1	20030501	US 2002-307321	20021202
				US 2001-812944	A3 20010327
FAN	2004:701812				
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004167184	A1	20040826	US 2003-715377	20031119
				US 2001-812940	B1 20010327
				US 2001-25947	A2 20011226
				US 2002-427567P	P 20021120
	US 2002143037	A1	20021003	US 2001-25947	20011226
				US 2001-812940	B1 20010327
OS	MARPAT 141:23197				
GI					



AB The invention relates to a preparation of amides of formula I [wherein: A is (hetero)cycloalk(en)yl, (hetero)aryl, etc.; Y1 and Y2 are independently selected from CH2, O, S, OC(O)O, NH, or -NHC(O)O-, etc.; L is (un)substituted C2-12 hydrocarbon chain optionally containing one double bond, at least one triple bond, or at least one double bond and one triple bond; R1 is H, alk(en/yn)yl, alkoxy, OH, etc.; R2 is H, alkyl, hydroxyalkyl, or haloalkyl, etc.], useful as histone deacetylase inhibitors. The invented compds. are claimed to be useful for the treatment of cystic fibrosis, chronic obstructive pulmonary disease, and asthma, etc. The prepared compds. were screened in cystic fibrosis assay (example 4 and 5) and for bronchial epithelial electrolyte transport (example 6). The mean inhibition of sodium transport for 7-phenyl-2,4,6-heptatrienoylhydroxamic acid was 69.2%. Inhibition of sodium transport by 7-phenyl-2,4,6-heptatrienoylhydroxamic acid was concentration-dependent with a half-maximal inhibitory concentration of 11.9  $\mu\text{M}$ . For instance, PhCH:CHCH:CHC(O)NHOH was prepared from PhCH:CHCH:CHCO2H and NH2OH•HCl in anhydrous DMF (example 2, no yield data).

=> d his

(FILE 'HOME' ENTERED AT 09:00:46 ON 21 SEP 2006)

FILE 'REGISTRY' ENTERED AT 09:01:11 ON 21 SEP 2006

E OXAMFLATIN/CN

L1 1 E3

FILE 'CAPLUS' ENTERED AT 09:01:51 ON 21 SEP 2006

L2 57 L1

L3 43283 SODIUM (L)TRANSPORT

L4 1 L2 AND L3

S 151720-43-3/REG#

FILE 'REGISTRY' ENTERED AT 09:15:23 ON 21 SEP 2006

L5 1 S 151720-43-3/RN

FILE 'CAPLUS' ENTERED AT 09:15:23 ON 21 SEP 2006

L6 57 S L5  
 L7 200642 LUNG  
 L8 10 L6 AND L7  
 L9 7 HYDOXAM?  
 L10 10111 HYDOXAM?  
 L11 9 L3(L)L10

=> l11 and l7

L12 1 L11 AND L7

=> d l12

L12 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:453179 CAPLUS

DN 141:23197

TI A preparation of unsaturated hydroxamic acid derivatives useful as histone deacetylase inhibitors

IN Wiech, Norbert L.; Lan-Hargest, Hsuan-yin

PA Circagen Pharmaceutical, USA; Beacon Laboratories

SO PCT Int. Appl., 27 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004046104	A2	20040603	WO 2003-US36981	20031119
	WO 2004046104	A3	20040805		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2506504	AA	20040603	CA 2003-2506504	20031119
	AU 2003291097	A1	20040615	AU 2003-291097	20031119
	EP 1567142	A2	20050831	EP 2003-783686	20031119
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006508986	T2	20060316	JP 2004-553939	20031119
PRAI	US 2002-427567P	P	20021120		
	WO 2003-US36981	W	20031119		
OS	MARPAT 141:23197				

=> .d his

2359045 D

59592 HIS

L13 245 .D HIS  
 (D(W)HIS)

=> d his

(FILE 'HOME' ENTERED AT 09:00:46 ON 21 SEP 2006)

FILE 'REGISTRY' ENTERED AT 09:01:11 ON 21 SEP 2006

E OXAMFLATIN/CN

L1 1 E3

FILE 'CAPLUS' ENTERED AT 09:01:51 ON 21 SEP 2006  
L2 57 L1  
L3 43283 SODIUM (L)TRANSPORT  
L4 1 L2 AND L3  
S 151720-43-3/REG#

FILE 'REGISTRY' ENTERED AT 09:15:23 ON 21 SEP 2006  
L5 1 S 151720-43-3/RN

FILE 'CAPLUS' ENTERED AT 09:15:23 ON 21 SEP 2006  
L6 57 S L5  
L7 200642 LUNG  
L8 10 L6 AND L7  
L9 7 HYDOXAM?  
L10 10111 HYDROXAM?  
L11 9 L3(L)L10  
L12 1 L11 AND L7  
L13 245 .D HIS

=> 110(1)17  
L14 85 L10(L)L7

=> lethal  
52569 LETHAL  
693 LETHALS  
L15 52885 LETHAL  
(LETHAL OR LETHALS)

=> 110(1)115  
L16 24 L10(L)L15

=> d 116 20-24 ti

L16 ANSWER 20 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN  
TI The effects of hydroxyurea and related compounds on the rat fetus

L16 ANSWER 21 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN  
TI Pharmacological effects of anthranilohydroxamic acid and certain other hydroxamic acids

L16 ANSWER 22 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN  
TI New potent reactivators of acetylcholinesterase inhibited by tetraethyl pyrophosphate

L16 ANSWER 23 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN  
TI Specific antidote treatment in prolonged poisoning with alkylphosphates in guinea pigs

L16 ANSWER 24 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN  
TI Hydroxamic acids as antitubercular agents

=> d 116 24

L16 ANSWER 24 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 1953:42136 CAPLUS  
DN 47:42136  
OREF 47:7092h-i,7093a  
TI Hydroxamic acids as antitubercular agents  
AU Urbanski, T.; Hornung, S.; Slopek, S.; Venulet, J.  
SO Nature (London, United Kingdom) (1952), 170, 753-4  
CODEN: NATUAS; ISSN: 0028-0836  
DT Journal

LA Unavailable

=> d 116 21 ti fbib abs

L16 ANSWER 21 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN

TI Pharmacological effects of anthranilohydroxamic acid and certain other hydroxamic acids

AN 1961:44535 CAPLUS

DN 55:44535

OREF 55:8643b-d

TI Pharmacological effects of anthranilohydroxamic acid and certain other hydroxamic acids

AU Bernheim, Frederick; Stoops, James K.

CS Duke Univ., Durham, NC

SO Proceedings of the Society for Experimental Biology and Medicine (1960), 105, 542-3

CODEN: PSEBAA; ISSN: 0037-9727

DT Journal

LA Unavailable

AB In rats, injection of anthranilohydroxamic acid, 1 mg./g. intraperitoneally, caused anesthesia lasting 10 hrs. or more. Half this dose caused tranquilization and suppression of the conditioned avoidance response. The compound protected mice against twice the lethal dose of strychnine and prolonged the life of animals given lethal doses of Metrazol or picrotoxin. In dogs, 1 g./kg. intravenously had no effect on heart rate, electrocardiogram, or blood pressure and only minor effects on respiration. Equivalent amts. of the hydroxamates of salicylic and benzoic acids had none of these effects.

=> poison?

L17 92484 POISON?

=> 110(1)117

L18 24 L10(L)L17

=> d 118 2-0-24 ti

'2-0-24' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS ----- GI and AB

ALL ----- BIB, AB, IND, RE

APPS ----- AI, PRAI

BIB ----- AN, plus Bibliographic Data and PI table (default)

CAN ----- List of CA abstract numbers without answer numbers

CBIB ----- AN, plus Compressed Bibliographic Data

CLASS ----- IPC, NCL, ECLA, FTERM

DALL ----- ALL, delimited (end of each field identified)

DMAX ----- MAX, delimited for post-processing

FAM ----- AN, PI and PRAI in table, plus Patent Family data

FBIB ----- AN, BIB, plus Patent FAM

IND ----- Indexing data

IPC ----- International Patent Classifications

MAX ----- ALL, plus Patent FAM, RE

PATS ----- PI, SO

SAM ----- CC, SX, TI, ST, IT

SCAN ----- CC, SX, TI, ST, IT (random display, no answer numbers;  
SCAN must be entered on the same line as the DISPLAY,  
e.g., D SCAN or DISPLAY SCAN)

STD ----- BIB, CLASS

IABS ----- ABS, indented with text labels  
 IALL ----- ALL, indented with text labels  
 IBIB ----- BIB, indented with text labels  
 IMAX ----- MAX, indented with text labels  
 ISTD ----- STD, indented with text labels  
  
 OBIB ----- AN, plus Bibliographic Data (original)  
 OIBIB ----- OBIB, indented with text labels  
  
 SBIB ----- BIB, no citations  
 SIBIB ----- IBIB, no citations  
  
 HIT ----- Fields containing hit terms  
 HITIND ----- IC, ICA, ICI, NCL, CC and index field (ST and IT)  
                   containing hit terms  
 HITRN ----- HIT RN and its text modification  
 HITSTR ----- HIT RN, its text modification, its CA index name, and  
                   its structure diagram  
 HITSEQ ----- HIT RN, its text modification, its CA index name, its  
                   structure diagram, plus NTE and SEQ fields  
 FHITSTR ----- First HIT RN, its text modification, its CA index name, and  
                   its structure diagram  
 FHITSEQ ----- First HIT RN, its text modification, its CA index name, its  
                   structure diagram, plus NTE and SEQ fields  
 KWIC ----- Hit term plus 20 words on either side  
 OCC ----- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field codes. For a list of the display field codes, enter HELP DFIELDS at an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST; TI,IND; TI,SO. You may specify the format fields in any order and the information will be displayed in the same order as the format specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC to view a specified Accession Number.  
 ENTER DISPLAY FORMAT (BIB):end

=> d 118 20-24 ti

L18 ANSWER 20 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN  
 TI New potent reactivators of acetylcholinesterase inhibited by tetraethyl pyrophosphate

L18 ANSWER 21 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN  
 TI Oximes and hydroxamic acids as antidotes in anticholinesterase poisoning

L18 ANSWER 22 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN  
 TI Toxicity of hydroxamic acid analogs; prophylactic and therapeutic efficacy against nerve gas poisoning in mice

L18 ANSWER 23 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN  
 TI Experimental chemotherapy of poisonings caused by phosphorus-containing antiesterases

L18 ANSWER 24 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN  
 TI The constitution of the fulminuric acids. VIII. Metal fulminuric acid

=> d 118 22 ti fbib abs



L18 ANSWER 22 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN  
 TI Toxicity of hydroxamic acid analogs; prophylactic and  
 therapeutic efficacy against nerve gas poisoning in mice  
 AN 1957:10194 CAPLUS  
 DN 51:10194  
 OREF 51:2169b-c  
 TI Toxicity of hydroxamic acid analogs; prophylactic and  
 therapeutic efficacy against nerve gas poisoning in mice  
 AU Epstein, Marvin A.; Freeman, Gustave; D'Agrosa, Louis S.; Dulz, Louis  
 CS Army Chem. Center, MD  
 SO Proceedings of the Society for Experimental Biology and Medicine (1956),  
 92, 660-2  
 CODEN: PSEBAA; ISSN: 0037-9727  
 DT Journal  
 LA Unavailable  
 AB A series of 17 hydroxamic acid analogs were tested for toxicity and for  
 ability to protect mice from a L.D.50 dose of Sarin. The toxicity varied  
 over a wide range. Some protected mice against Sarin when administered in  
 huge doses. The protective activity was unrelated to the relative  
 toxicity.

=> d 118 9-19 ti

L18 ANSWER 9 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN  
 TI Cyanide-insensitive oxygen uptake and pyridine nucleotide dehydrogenases  
 in the cyanobacterium Anabaena PCC 7120

L18 ANSWER 10 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN  
 TI A lead(II) ion selective electrode via a metal complex of poly(hydroxamic  
 acid)

L18 ANSWER 11 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN  
 TI Structures and functions of fungal siderophores containing hydroxamate and  
 complexone type iron binding ligands

L18 ANSWER 12 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN  
 TI Polymeric iron chelators

L18 ANSWER 13 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN  
 TI Cholinesterase inhibition method for estimation of some organophosphate  
 insecticides in forensic toxicology

L18 ANSWER 14 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN  
 TI Comparative protective activities of chromone-2-carboxyhydroxamic acid  
 (sodium salt), methionine, and disodium tetracemate in experimental  
 mercuric chloride poisoning in mice. Variations of lactate dehydrogenase  
 and of its humoral and tissue isoenzymes

L18 ANSWER 15 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN  
 TI Iron metabolism: siderochromes

L18 ANSWER 16 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN  
 TI Reaction of 4-formyl-1-methylpyridinium iodide oxime with isopropyl  
 methylphosphonofluoridate

L18 ANSWER 17 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN  
 TI Synthesis and fungicidal activity of aryloxyalkanehydroxamic acids and  
 analogs

L18 ANSWER 18 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN  
 TI Properties and fungicidal activity of aryloxyacetohydroxamic acids

L18 ANSWER 19 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN

TI The activation of the fatty acids in the liver in different experimental conditions

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

133.42

165.09

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-9.75

-11.25

FILE 'REGISTRY' ENTERED AT 10:12:54 ON 21 SEP 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 20 SEP 2006 HIGHEST RN 908067-83-4

DICTIONARY FILE UPDATES: 20 SEP 2006 HIGHEST RN 908067-83-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

Effective September 24, 2006, Concord 3D coordinates will no longer be available. Please contact CAS Customer Care (<http://www.cas.org/supp.html>) if you have a need for 3D coordinates.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> e trichostatin/cn

E1 1 TRICHOSTATIC ACID/CN

E2 1 TRICHOSTATIC ACID METHYL ESTER/CN

E3 1 --> TRICHOSTATIN/CN

E4 1 TRICHOSTATIN A/CN

E5 1 TRICHOSTATIN A AMIDE/CN

E6 1 TRICHOSTATIN B/CN

E7 1 TRICHOSTATIN C/CN

E8 1 TRICHOSTATIN D/CN

E9 1 TRICHOSTATIN RK/CN

E10 1 TRICHOSTIN/CN

E11 1 TRICHOSURIN (TRICHOSURUS VULPECULA MAMMARY GLAND PRECURSOR)/CN

E12 1 TRICHOTETROL/CN

=> e3

L19 1 TRICHOSTATIN/CN

=> d 119

L19 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN  
RN 119978-65-3 REGISTRY  
ED Entered STN: 07 Apr 1989  
CN Trichostatin (9CI) (CA INDEX NAME)  
MF Unspecified  
CI MAN  
SR CA  
LC STN Files: AGRICOLA, BIOSIS, CA, CAPLUS, CIN, TOXCENTER, USPAT2,  
USPATFULL

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

57 REFERENCES IN FILE CA (1907 TO DATE)

3 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

58 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> fiole caplus

0 FIOLE

0 CAPLUS

L20 0 FIOLE CAPLUS

(FIOLE(W)CAPLUS)

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

17.06

182.15

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-11.25

FILE 'CAPLUS' ENTERED AT 10:14:03 ON 21 SEP 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 21 Sep 2006 VOL 145 ISS 13

FILE LAST UPDATED: 20 Sep 2006 (20060920/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> l19

L21 58 L19

=> d his

(FILE 'HOME' ENTERED AT 09:00:46 ON 21 SEP 2006)

FILE 'REGISTRY' ENTERED AT 09:01:11 ON 21 SEP 2006

E OXAMFLATIN/CN

L1 1 E3

FILE 'CAPLUS' ENTERED AT 09:01:51 ON 21 SEP 2006

L2 57 L1

L3 43283 SODIUM (L)TRANSPORT

L4 1 L2 AND L3  
S 151720-43-3/REG#

FILE 'REGISTRY' ENTERED AT 09:15:23 ON 21 SEP 2006

L5 1 S 151720-43-3/RN

FILE 'CAPLUS' ENTERED AT 09:15:23 ON 21 SEP 2006

L6 57 S L5

L7 200642 LUNG

L8 10 L6 AND L7

L9 7 HYDOXAM?

L10 10111 HYDROXAM?

L11 9 L3(L)L10

L12 1 L11 AND L7

L13 245 .D HIS

L14 85 L10(L)L7

L15 52885 LETHAL

L16 24 L10(L)L15

L17 92484 POISON?

L18 24 L10(L)L17

FILE 'REGISTRY' ENTERED AT 10:12:54 ON 21 SEP 2006

E TRICHOSTATIN/CN

L19 1 E3

L20 0 FIOLE CAPLUS

FILE 'CAPLUS' ENTERED AT 10:14:03 ON 21 SEP 2006

L21 58 L19

=> l7 and l21

L22 5 L7 AND L21

=> d l22 1-5 ti

L22 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

TI Aberrant methylation of the eyes absent 4 gene in ulcerative colitis-associated dysplasia

L22 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

TI Regulation of the p21 gene and uses thereof

L22 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

TI Treatment of lung cells with histone deacetylase inhibitors

L22 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

TI A preparation of unsaturated hydroxamic acid derivatives useful as histone deacetylase inhibitors

L22 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

TI Ineffectiveness of Histone Deacetylase Inhibitors to Induce Apoptosis  
Involves the Transcriptional Activation of NF- $\kappa$ B through the Akt Pathway

=> d l22 5 ti fbib abs

L22 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

TI Ineffectiveness of Histone Deacetylase Inhibitors to Induce Apoptosis  
Involves the Transcriptional Activation of NF- $\kappa$ B through the Akt  
Pathway

AN 2003:380703 CAPLUS

DN 139:127585

TI Ineffectiveness of Histone Deacetylase Inhibitors to Induce Apoptosis  
Involves the Transcriptional Activation of NF- $\kappa$ B through the Akt  
Pathway

AU Mayo, Marty W.; Denlinger, Chadrick E.; Broad, Robert M.; Yeung, Fan;  
Reilly, Eugene T.; Shi, Yang; Jones, David R.

CS Dep. Surg., Univ. Virginia, Charlottesville, VA, 22908, USA

SO Journal of Biological Chemistry (2003), 278(21), 18980-18989

CODEN: JBCHA3; ISSN: 0021-9258

PB American Society for Biochemistry and Molecular Biology

DT Journal

LA English

AB Histone deacetylase (HDAC) inhibitors are emerging as a new class of anticancer agents for the treatment of solid and hematol. malignancies. Although HDAC inhibitors induce cell death through an apoptotic process, little is known about the mol. events that control their effectiveness. In this study, we demonstrate that HDAC inhibitors are limited in their ability to induce apoptosis in non-small cell lung cancer (NSCLC) cell lines despite their ability to effectively inhibit deacetylase activity. Because the anti-apoptotic transcription factor NF- $\kappa$ B has been shown to be under the control of HDAC-mediated repression, we analyzed whether HDAC inhibitors activated NF- $\kappa$ B in NSCLC cells. HDAC inhibitors effectively stimulated endogenous NF- $\kappa$ B-dependent gene expression by up-regulating IL-8, Bcl-XL, and MMP-9 transcripts. The ability of HDAC inhibitors to increase NF- $\kappa$ B transcriptional activity was not associated with signaling events that stimulated nuclear translocation, but rather modulated the transactivation potential of the RelA/p65 subunit of NF- $\kappa$ B. The inhibition of HDAC activity was associated with the recruitment of the p300 transcriptional co-activator to chromatin in an Akt-dependent manner. Moreover, Akt directly phosphorylated p300 in vitro and was required for stimulating the transactivation potential of the co-activator following the addition of HDAC inhibitors. Selective inhibition of either the phosphoinositide 3-kinase/Akt pathway, or NF- $\kappa$ B itself blocked the ability of HDAC inhibitors to activate NF- $\kappa$ B and dramatically sensitized NSCLC cells to apoptosis following the addition of HDAC inhibitors. Our study indicates that the ineffectiveness of HDAC inhibitors to induce apoptosis in NSCLC cancer cells is associated with the ability of these mols. to stimulate NF- $\kappa$ B-dependent transcription and cell survival.

RE.CNT 64 THERE ARE 64 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> oxyamide

19 OXYAMIDE

10 OXYAMIDES

L23

27 OXYAMIDE

(OXYAMIDE OR OXYAMIDES)

=> d 123 20-27 ti

L23 ANSWER 20 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN

TI Irreversible enzyme inhibitors. CLXXIX. Active-site-directed irreversible enzyme inhibitors of dihydrofolate reductase from 1-(3-chlorophenyl)-4,6-diamino-1,2-dihydro-2,2-dimethyl-s-triazine with oxyamide bridges to a terminal sulfonyl fluoride

L23 ANSWER 21 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN

TI New type of stable tetrapolar phosphorus ylide

L23 ANSWER 22 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN  
TI Kinetics of the formation of aluminum oxyamide by ammonolysis of the oxychloride

L23 ANSWER 23 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN  
TI Infrared spectroscopic study of the oxyamide and thioamide of aluminum

L23 ANSWER 24 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN  
TI Flavone-7-oxyacetamides

L23 ANSWER 25 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN  
TI A new compound of trivalent iron: the oxyamide  $\text{FeO}(\text{NH}_2)$

L23 ANSWER 26 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN  
TI Effect of non-ionic demulsifying agents on the desalting of Romashkino crude oil

L23 ANSWER 27 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN  
TI Aminoplasts containing silicon

=> d l23 1-19 ti

L23 ANSWER 1 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN  
TI Photosensitive composition and lithographic printing plate precursor

L23 ANSWER 2 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN  
TI Treatment of lung cells with histone deacetylase inhibitors

L23 ANSWER 3 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN  
TI Production L- $\alpha$ -oxy acids by enzymic resolution

L23 ANSWER 4 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN  
TI Bactericidal antimicrobial methods and compositions using acyl hydrazides, oxyamides, and 8-hydroxyquinolines as antibiotic potentiators for treatment of Gram-positive infections

L23 ANSWER 5 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN  
TI Synthesis of N-benzyl-indolyl(benzyloxy)amido derivatives as PDE-IV inhibitors

L23 ANSWER 6 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN  
TI Manufacture of optically-active oxyamines by enzymic stereoselective hydrolysis of oxyamides

L23 ANSWER 7 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN  
TI Water- and hydroxyl group-free gels and xerogels based on a network of oxygen-bridged metal and/or semimetal atoms, and their manufacture and use

L23 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN  
TI Synthesis of an oxyamide linked nucleotide dimer and incorporation into antisense oligonucleotide sequences

L23 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN  
TI The thermal transformation of aromatic amides

L23 ANSWER 10 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN  
TI The thermal transformation of an aromatic poly(amide), poly(ortho-oxyamide) and poly(benzoxazole)

L23 ANSWER 11 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN

TI Reaction of benzohydroxamic acid with N-glycidyl-N-ethylaniline

L23 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN  
 TI New dihydrazido and oxyamido derivatives of phosphoric and thiophosphoric acid with bis(2-chloroethyl)amido substituents

L23 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN  
 TI Synthesis of fluorescent peptidyl thioneamides and the assay of papain in the presence of trypsin

L23 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN  
 TI N-Oxyamides and their use as fungicides

L23 ANSWER 15 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN  
 TI Basic methanolysis of N-aryl-N-methylthiobenzamides

L23 ANSWER 16 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN  
 TI Heat-resisting film

L23 ANSWER 17 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN  
 TI Polymer compositions for films

L23 ANSWER 18 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN  
 TI Heat-resistant polyimides or -imidazopyrrolones


L23 ANSWER 19 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN  
 TI Molecular weight determination of benzene-containing compounds by ultraviolet spectrometry

=> d l23 14 ti fbib abs


L23 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN  
 TI N-Oxyamides and their use as fungicides  
 AN 1982:455463 CAPLUS  
 DN 97:55463  
 TI N-Oxyamides and their use as fungicides  
 IN Stetter, Joerg; Fuehrer, Wolfgang; Brandes, Wilhelm  
 PA Bayer A.-G. , Fed. Rep. Ger.  
 SO Eur. Pat. Appl., 43 pp.  
 CODEN: EPXXDW  
 DT Patent  
 LA German  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 46931	A2	19820310	EP 1981-106468	19810820
	EP 46931	A3	19820317		
	R: AT, BE, CH, DE, FR, GB, IT, NL, SE				
	DE 3033160	A1	19820422	DE 1980-3033160	A 19800903
	JP 57077650	A2	19820515	DE 1980-3033160	19800903
				JP 1981-136223	19810901
				DE 1980-3033160	A 19800903
	DK 8103879	A	19820304	DK 1981-3879	19810902
				DE 1980-3033160	A 19800903
	AU 8174864	A1	19820311	AU 1981-74864	19810902
				DE 1980-3033160	A 19800903
	BR 8105613	A	19820518	BR 1981-5613	19810902
				DE 1980-3033160	19800903
	ES 505137	A1	19820816	ES 1981-505137	19810902
				DE 1980-3033160	A 19800903
	ZA 8106082	A	19820825	ZA 1981-6082	19810902
				DE 1980-3033160	A 19800903

GI



I



II

AB Amides I [R<sub>1</sub> = H, alkyl, halo; R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> = H, alkyl; R<sub>5</sub>, R<sub>6</sub> = H, halogen (un)substituted aliphatic group; R<sub>5</sub>R<sub>6</sub> = alkylene; R<sub>7</sub> = furyl, thienyl, tetrahydrofuryl, tetrahydrothienyl, aliphatic group (un)substituted with halogen, cyano, or thiocyanato, CH<sub>2</sub>R (R = pyrazolyl, 1,2,4-triazolyl, imidazolyl), CH<sub>2</sub>OR<sub>8</sub> [R<sub>8</sub> = (un)substituted aliphatic group or alkoxyalkyl], CH<sub>2</sub>SR<sub>8</sub>, OR<sub>8</sub>, SR<sub>8</sub>, CH<sub>2</sub>OSO<sub>2</sub>R<sub>8</sub>, CO<sub>2</sub>R<sub>8</sub>, tetrahydropyranyloxymethyl], useful as agricultural fungicides (no data), were prepared Thus, treating 2,6-Me<sub>2</sub>C<sub>6</sub>H<sub>3</sub>N(COCH<sub>2</sub>OMe)CHMeCO<sub>2</sub>H and MeONH<sub>2</sub>.HCl containing NEt<sub>3</sub> in CH<sub>2</sub>Cl<sub>2</sub> with dicyclohexylcarbodiimide gave 36% 2,6-Me<sub>2</sub>C<sub>6</sub>H<sub>3</sub>N(COCH<sub>2</sub>OMe)CHMeCONHOMe which was methylated with Me<sub>2</sub>SO<sub>4</sub> in 50% NaOH-PhMe containing PhCH<sub>2</sub>N<sup>+</sup>Et<sub>3</sub>.Cl<sup>-</sup> to give 45% amide II.

=> airway epithelial  
 21836 AIRWAY  
 9399 AIRWAYS  
 25960 AIRWAY  
 (AIRWAY OR AIRWAYS)  
 106608 EPITHELIAL  
 8 EPITHELIALS  
 106612 EPITHELIAL  
 (EPITHELIAL OR EPITHELIALS)  
 L24 2371 AIRWAY EPITHELIAL  
 (AIRWAY(W) EPITHELIAL)

=> d his

(FILE 'HOME' ENTERED AT 09:00:46 ON 21 SEP 2006)  
 FILE 'REGISTRY' ENTERED AT 09:01:11 ON 21 SEP 2006  
 E OXAMFLATIN/CN  
 L1 1 E3  
 FILE 'CAPLUS' ENTERED AT 09:01:51 ON 21 SEP 2006  
 L2 57 L1  
 L3 43283 SODIUM (L)TRANSPORT  
 L4 1 L2 AND L3  
 S 151720-43-3/REG#  
 FILE 'REGISTRY' ENTERED AT 09:15:23 ON 21 SEP 2006  
 L5 1 S 151720-43-3/RN  
 FILE 'CAPLUS' ENTERED AT 09:15:23 ON 21 SEP 2006  
 L6 57 S L5  
 L7 200642 LUNG  
 L8 10 L6 AND L7  
 L9 7 HYDOXAM?  
 L10 10111 HYDOXAM?  
 L11 9 L3(L)L10  
 L12 1 L11 AND L7



L13 245 .D HIS  
L14 85 L10(L)L7  
L15 52885 LETHAL  
L16 24 L10(L)L15  
L17 92484 POISON?  
L18 24 L10(L)L17

FILE 'REGISTRY' ENTERED AT 10:12:54 ON 21 SEP 2006  
E TRICHOSTATIN/CN

L19 1 E3  
L20 0 FIOLE CAPLUS

FILE 'CAPLUS' ENTERED AT 10:14:03 ON 21 SEP 2006

L21 58 L19  
L22 5 L7 AND L21  
L23 27 OXYAMIDE  
L24 2371 AIRWAY EPITHELIAL

=> 110 and 124

L25 1 L10 AND L24

=> 13 and 125

L26 0 L3 AND L25

=> logoff hold

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
29.71	211.86

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-1.50	-12.75

CA SUBSCRIBER PRICE

SESSION WILL BE HELD FOR 60 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 10:24:26 ON 21 SEP 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:

\* \* \* \* \* RECONNECTED TO STN INTERNATIONAL \* \* \* \* \*

SESSION RESUMED IN FILE 'CAPLUS' AT 10:44:44 ON 21 SEP 2006

FILE 'CAPLUS' ENTERED AT 10:44:44 ON 21 SEP 2006

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
29.71	211.86

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-1.50	-12.75

CA SUBSCRIBER PRICE

=> logoff hold

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
30.17	212.32

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

CA SUBSCRIBER PRICE

ENTRY  
-1.50

SESSION  
-12.75

SESSION WILL BE HELD FOR 60 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 10:45:06 ON 21 SEP 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS	4	MAY 10	CA/CAPLUS enhanced with 1900-1906 U.S. patent records
NEWS	5	MAY 11	KOREAPAT updates resume
NEWS	6	MAY 19	Derwent World Patents Index to be reloaded and enhanced
NEWS	7	MAY 30	IPC 8 Rolled-up Core codes added to CA/CAPLUS and USPATFULL/USPAT2
NEWS	8	MAY 30	The F-Term thesaurus is now available in CA/CAPLUS
NEWS	9	JUN 02	The first reclassification of IPC codes now complete in INPADOC
NEWS	10	JUN 26	TULSA/TULSA2 reloaded and enhanced with new search and and display fields
NEWS	11	JUN 28	Price changes in full-text patent databases EPFULL and PCTFULL
NEWS	12	JUL 11	CHEMSAFE reloaded and enhanced
NEWS	13	JUL 14	FSTA enhanced with Japanese patents
NEWS	14	JUL 19	Coverage of Research Disclosure reinstated in DWPI
NEWS	15	AUG 09	INSPEC enhanced with 1898-1968 archive
NEWS	16	AUG 28	ADISCTI Reloaded and Enhanced
NEWS	17	AUG 30	CA(SM)/CAPLUS(SM) Austrian patent law changes
NEWS	18	SEP 11	CA/CAPLUS enhanced with more pre-1907 records
NEWS	19	SEP 21	CA/CAPLUS fields enhanced with simultaneous left and right truncation
NEWS EXPRESS		JUNE 30	CURRENT WINDOWS VERSION IS V8.01b, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8
NEWS X25			X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may

result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 12:04:22 ON 21 SEP 2006

=> logoff hold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

SESSION WILL BE HELD FOR 60 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 12:04:44 ON 21 SEP 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:

\* \* \* \* \* RECONNECTED TO STN INTERNATIONAL \* \* \* \* \*  
SESSION RESUMED IN FILE 'HOME' AT 12:09:55 ON 21 SEP 2006  
FILE 'HOME' ENTERED AT 12:09:55 ON 21 SEP 2006

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 12:10:08 ON 21 SEP 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 20 SEP 2006 HIGHEST RN 908067-83-4

DICTIONARY FILE UPDATES: 20 SEP 2006 HIGHEST RN 908067-83-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

Effective September 24, 2006, Concord 3D coordinates will no longer  
be available. Please contact CAS Customer Care  
(<http://www.cas.org/supp.html>) if you have a need for 3D coordinates.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006


Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Documents and Settings\PZucker\My Documents\Examination Auxillary files\10715377\10715377 arylalkenylhydroxamic.str



chain nodes :

7 8 9 10 11 12 13 14

ring nodes :

1 2 3 4 5 6

chain bonds :

5-7 7-8 8-9 9-10 10-11 11-12 11-13 12-14

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6

exact/norm bonds :

11-12 11-13

exact bonds :

5-7 7-8 8-9 9-10 10-11 12-14

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS  
11:CLASS 12:CLASS 13:CLASS 14:CLASS

L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> search 11 sss sam

SAMPLE SEARCH INITIATED 12:10:31 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 226 TO ITERATE

100.0% PROCESSED 226 ITERATIONS 50 ANSWERS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01


FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 3619 TO 5421  
PROJECTED ANSWERS: 1674 TO 2966

L2 50 SEA SSS SAM L1

=> d scan

L2 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN 2-Propenamide, 3-[2,3-dihydro-1-[[2-(1H-indol-3-yl)ethyl][[4-(4-morpholinylcarbonyl)-1H-pyrrol-2-yl]methyl]amino]-1H-inden-5-yl]-N-hydroxy-, (2E)- (9CI)  
MF C32 H35 N5 O4

Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> 0

L3 853427 0

=>

Uploading C:\Documents and Settings\PZucker\My Documents\Examination Auxillary  
files\10715377\10715377 fixedHarylalkenylhydrox.str



chain nodes :  
 7 8 9 10 11 12 13 14  
 ring nodes :  
 1 2 3 4 5 6  
 chain bonds :  
 5-7 7-8 8-9 9-10 10-11 11-12 11-13 12-14  
 ring bonds :  
 1-2 1-6 2-3 3-4 4-5 5-6  
 exact/norm bonds :  
 11-12 11-13  
 exact bonds :  
 5-7 7-8 8-9 9-10 10-11 12-14  
 normalized bonds :  
 1-2 1-6 2-3 3-4 4-5 5-6


Hydrogen count :  
 1:>= minimum 1 2:>= minimum 1 3:>= minimum 1 4:>= minimum 1 6:>= minimum 1  
 7:>= minimum 1 8:>= minimum 1 9:>= minimum 1 10:>= minimum 1  
 Match level :  
 1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS  
 11:CLASS 12:CLASS 13:CLASS 14:CLASS

L4 STRUCTURE UPLOADED

=> d 14

L4 HAS NO ANSWERS

L4 STR



Structure attributes must be viewed using STN Express query preparation.

=> search 14 sss sam

SAMPLE SEARCH INITIATED 12:13:16 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 226 TO ITERATE

100.0% PROCESSED 226 ITERATIONS  
SEARCH TIME: 00.00.01

0 ANSWERS

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 3619 TO 5421  
PROJECTED ANSWERS: 0 TO 0

L5 0 SEA SSS SAM L4

=> search 14 sss full

FULL SEARCH INITIATED 12:13:25 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 4438 TO ITERATE


100.0% PROCESSED 4438 ITERATIONS  
SEARCH TIME: 00.00.01

11 ANSWERS

L6 11 SEA SSS FUL L4

=> d scan

L6 11 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN 2-Propenamide, N-hydroxy-3-phenyl-, monosodium salt (9CI)  
MF C9 H9 N O2 . Na




● Na

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):11


L6 11 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN 2,4-Pentadienamide, N-hydroxy-5-phenyl-, (2E,4E)- (9CI)  
MF C11 H11 N O2

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L6 11 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN 2,4,6-Heptatrienamide, N-hydroxy-7-phenyl- (9CI)  
MF C13 H13 N O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L6 11 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN 2-Propenamide, N-hydroxy-3-phenyl-, monopotassium salt (9CI)  
 MF C9 H9 N O2 . K




● K

L6 11 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN 2-Propenamide, N-hydroxy-3-phenyl-, compd. with N-[2-[(4-amino-3-methylphenyl)ethylamino]ethyl]methanesulfonamide (1:1) (9CI)  
 MF C12 H21 N3 O2 S . C9 H9 N O2

CM 1




CM 2



L6 11 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN 2-Propenamide, N-hydroxy-3-phenyl-, (2E)- (9CI)  
 MF C9 H9 N O2


Double bond geometry as shown.





\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L6 11 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN 2-Propenamide, N-hydroxy-3-phenyl- (9CI)  
 MF C9 H9 N O2  
 CI COM



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L6 11 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN 2,4,6-Heptatrienamide, N-hydroxy-7-phenyl-, (2E,4E,6E)- (9CI)  
 MF C13 H13 N O2

Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L6 11 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN 2,4-Pentadienamide, N-hydroxy-5-phenyl- (9CI)  
 MF C11 H11 N O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L6 11 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN 2-Propenamide, N-hydroxy-3-phenyl-, (Z)- (9CI)  
 MF C9 H9 N O2

Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L6 11 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN 2-Propenamide, N-hydroxy-3-phenyl-, calcium salt (2:1) (9CI)  
 MF C9 H9 N O2 . 1/2 Ca



● 1/2 Ca

ALL ANSWERS HAVE BEEN SCANNED

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

173.90

174.11

FILE 'CAPLUS' ENTERED AT 12:13:53 ON 21 SEP 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 21 Sep 2006 VOL 145 ISS 13

FILE LAST UPDATED: 20 Sep 2006 (20060920/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> 16

L7 104 L6

=> asthma or bronchitis or COPD

```

32308 ASTHMA
  21 ASTHMAS
32316 ASTHMA
      (ASTHMA OR ASTHMAS)
5800 BRONCHITIS
2762 COPD
  15 COPDS
2775 COPD
      (COPD OR COPDS)
L8      37979 ASTHMA OR BRONCHITIS OR COPD

```

=> 17 and 18

```
L9      3 L7 AND L8
```

=> d 19 n1-3 ti fbib abs

'N1-3' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

```

ABS ----- GI and AB
ALL ----- BIB, AB, IND, RE
APPS ----- AI, PRAI
BIB ----- AN, plus Bibliographic Data and PI table (default)
CAN ----- List of CA abstract numbers without answer numbers
CBIB ----- AN, plus Compressed Bibliographic Data
CLASS ----- IPC, NCL, ECLA, FTERM
DALL ----- ALL, delimited (end of each field identified)
DMAX ----- MAX, delimited for post-processing
FAM ----- AN, PI and PRAI in table, plus Patent Family data
FBIB ----- AN, BIB, plus Patent FAM
IND ----- Indexing data
IPC ----- International Patent Classifications
MAX ----- ALL, plus Patent FAM, RE
PATS ----- PI, SO
SAM ----- CC, SX, TI, ST, IT
SCAN ----- CC, SX, TI, ST, IT (random display, no answer numbers;
      SCAN must be entered on the same line as the DISPLAY,
      e.g., D SCAN or DISPLAY SCAN)
STD ----- BIB, CLASS

IABS ----- ABS, indented with text labels
IALL ----- ALL, indented with text labels
IBIB ----- BIB, indented with text labels
IMAX ----- MAX, indented with text labels
ISTD ----- STD, indented with text labels

OBIB ----- AN, plus Bibliographic Data (original)
OIBIB ----- OBIB, indented with text labels

SBIB ----- BIB, no citations
SIBIB ----- IBIB, no citations

HIT ----- Fields containing hit terms
HITIND ----- IC, ICA, ICI, NCL, CC and index field (ST and IT)
      containing hit terms
HITRN ----- HIT RN and its text modification
HITSTR ----- HIT RN, its text modification, its CA index name, and
      its structure diagram
HITSEQ ----- HIT RN, its text modification, its CA index name, its
      structure diagram, plus NTE and SEQ fields
FHITSTR ----- First HIT RN, its text modification, its CA index name, and
      its structure diagram
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its

```

structure diagram, plus NTE and SEQ fields  
KWIC ----- Hit term plus 20 words on either side  
OCC ----- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field codes. For a list of the display field codes, enter HELP DFIELDS at an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST; TI,IND; TI,SO. You may specify the format fields in any order and the information will be displayed in the same order as the format specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC to view a specified Accession Number.

ENTER DISPLAY FORMAT (BIB):e4nd  
'E4ND' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS ----- GI and AB  
ALL ----- BIB, AB, IND, RE  
APPS ----- AI, PRAI  
BIB ----- AN, plus Bibliographic Data and PI table (default)  
CAN ----- List of CA abstract numbers without answer numbers  
CBIB ----- AN, plus Compressed Bibliographic Data  
CLASS ----- IPC, NCL, ECLA, FTERM  
DALL ----- ALL, delimited (end of each field identified)  
DMAX ----- MAX, delimited for post-processing  
FAM ----- AN, PI and PRAI in table, plus Patent Family data  
FBIB ----- AN, BIB, plus Patent FAM  
IND ----- Indexing data  
IPC ----- International Patent Classifications  
MAX ----- ALL, plus Patent FAM, RE  
PATS ----- PI, SO  
SAM ----- CC, SX, TI, ST, IT  
SCAN ----- CC, SX, TI, ST, IT (random display, no answer numbers;  
SCAN must be entered on the same line as the DISPLAY,  
e.g., D SCAN or DISPLAY SCAN)  
STD ----- BIB, CLASS  
  
IABS ----- ABS, indented with text labels  
IALL ----- ALL, indented with text labels  
IBIB ----- BIB, indented with text labels  
IMAX ----- MAX, indented with text labels  
ISTD ----- STD, indented with text labels  
  
OBIB ----- AN, plus Bibliographic Data (original)  
OIBIB ----- OBIB, indented with text labels  
  
SBIB ----- BIB, no citations  
SIBIB ----- IBIB, no citations  
  
HIT ----- Fields containing hit terms  
HITIND ----- IC, ICA, ICI, NCL, CC and index field (ST and IT)  
containing hit terms  
HITRN ----- HIT RN and its text modification  
HITSTR ----- HIT RN, its text modification, its CA index name, and  
its structure diagram  
HITSEQ ----- HIT RN, its text modification, its CA index name, its  
structure diagram, plus NTE and SEQ fields  
FHITSTR ----- First HIT RN, its text modification, its CA index name, and  
its structure diagram  
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its

structure diagram, plus NTE and SEQ fields  
 KWIC ----- Hit term plus 20 words on either side  
 OCC ----- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field codes. For a list of the display field codes, enter HELP DFIELDS at an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST; TI,IND; TI,SO. You may specify the format fields in any order and the information will be displayed in the same order as the format specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC to view a specified Accession Number.

ENTER DISPLAY FORMAT (BIB):\end  
 '\END' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS ----- GI and AB  
 ALL ----- BIB, AB, IND, RE  
 APPS ----- AI, PRAI  
 BIB ----- AN, plus Bibliographic Data and PI table (default)  
 CAN ----- List of CA abstract numbers without answer numbers  
 CBIB ----- AN, plus Compressed Bibliographic Data  
 CLASS ----- IPC, NCL, ECLA, FTERM  
 DALL ----- ALL, delimited (end of each field identified)  
 DMAX ----- MAX, delimited for post-processing  
 FAM ----- AN, PI and PRAI in table, plus Patent Family data  
 FBIB ----- AN, BIB, plus Patent FAM  
 IND ----- Indexing data  
 IPC ----- International Patent Classifications  
 MAX ----- ALL, plus Patent FAM, RE  
 PATS ----- PI, SO  
 SAM ----- CC, SX, TI, ST, IT  
 SCAN ----- CC, SX, TI, ST, IT (random display, no answer numbers;  
                   SCAN must be entered on the same line as the DISPLAY,  
                   e.g., D SCAN or DISPLAY SCAN)  
 STD ----- BIB, CLASS  
  
 IABS ----- ABS, indented with text labels  
 IALL ----- ALL, indented with text labels  
 IBIB ----- BIB, indented with text labels  
 IMAX ----- MAX, indented with text labels  
 ISTD ----- STD, indented with text labels  
  
 OBIB ----- AN, plus Bibliographic Data (original)  
 OIBIB ----- OBIB, indented with text labels  
  
 SBIB ----- BIB, no citations  
 SIBIB ----- IBIB, no citations  
  
 HIT ----- Fields containing hit terms  
 HITIND ----- IC, ICA, ICI, NCL, CC and index field (ST and IT)  
                   containing hit terms  
 HITRN ----- HIT RN and its text modification  
 HITSTR ----- HIT RN, its text modification, its CA index name, and  
                   its structure diagram  
 HITSEQ ----- HIT RN, its text modification, its CA index name, its  
                   structure diagram, plus NTE and SEQ fields  
 FHITSTR ----- First HIT RN, its text modification, its CA index name, and  
                   its structure diagram  
 FHITSEQ ----- First HIT RN, its text modification, its CA index name, its

structure diagram, plus NTE and SEQ fields  
 KWIC ----- Hit term plus 20 words on either side  
 OCC ----- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field codes. For a list of the display field codes, enter HELP DFIELDS at an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST; TI,IND; TI,SO. You may specify the format fields in any order and the information will be displayed in the same order as the format specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC to view a specified Accession Number.  
 ENTER DISPLAY FORMAT (BIB):end

=> d 19 1-3 ti fbib abs

L9 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN  
 TI Formulation comprising histone deacetylase inhibitor exhibiting biphasic release  
 AN 2005:1168848 CAPLUS  
 DN 143:446691  
 TI Formulation comprising histone deacetylase inhibitor exhibiting biphasic release  
 IN Franke, Hanshermann; Lennartz, Peter; Maurer, Alexander, B.; Hentsch, Bernd; Hoevelmann, Sascha; Martin, Elke  
 PA G2M Cancer Drugs A.-G., Germany; Desitin Arzneimittel G.m.b.H.  
 SO Eur. Pat. Appl., 29 pp.  
 CODEN: EPXXDW

DT Patent  
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1591109	A1	20051102	EP 2004-10333	20040430
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	WO 2005105055	A1	20051110	WO 2005-EP4739	20050502
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

EP 2004-10333 A 20040430

OS MARPAT 143:446691

AB The present invention relates to an orally available galenics formulation of Valproic Acid or derivs. thereof exhibiting a specific bi-phasic pharmacokinetic profile optimized for maximum inhibition of histone deacetylases in a therapeutic setting. This specific galenics formulation is designed for the treatment of malignant diseases and diseases associated with hypoacetylation of histones or in which induction of hyperacetylation has a beneficial effect, e.g., by induction of differentiation and/or apoptosis. Due to the bi-phasic release pattern the resulting pharmacokinetic profile is able to inhibit HDAC target enzymes most efficiently and to subsequently induce histone hyperacetylation in a rapid

as well as a long-lasting fashion. This profile secures the efficient modulation of a desired target gene expression profile which contributes to the therapeutic benefit.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN  
TI Treatment of lung cells with histone deacetylase inhibitors  
AN 2004:701812 CAPLUS  
DN 141:167803  
TI Treatment of lung cells with histone deacetylase inhibitors  
IN Wiech, Norbert L.; Lan-Hargest, Hsuan-Yin  
PA USA  
SO U.S. Pat. Appl. Publ., 10 pp., Cont.-in-part of U.S. Ser. No. 25,947.  
CODEN: USXXCO  
DT Patent  
LA English  
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004167184	A1	20040826	US 2003-715377	20031119
				US 2001-812940	B1 20010327
				US 2001-25947	A2 20011226
				US 2002-427567P	P 20021120
	US 2002143037	A1	20021003	US 2001-25947	20011226
				US 2001-812940	B1 20010327

PATENT FAMILY INFORMATION:

FAN 2002:754352

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002076941	A2	20021003	WO 2002-US8836	20020325
	WO 2002076941	A3	20040212		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2001-812940	A1 20010327
				US 2001-812944	A1 20010327
				US 2001-812945	A1 20010327
				US 2001-25947	A1 20011226
	US 2002143196	A1	20021003	US 2001-812944	20010327
	US 6495719	B2	20021217		
	US 2002143052	A1	20021003	US 2001-812945	20010327
	US 2002143037	A1	20021003	US 2001-25947	20011226
				US 2001-812940	B1 20010327
	CA 2442366	AA	20021003	CA 2002-2442366	20020325
				US 2001-812940	A 20010327
				US 2001-812944	A 20010327
				US 2001-812945	A 20010327
				US 2001-25947	A 20011226
				WO 2002-US8836	W 20020325
	AU 2002250401	A1	20021008	AU 2002-250401	20020325
				US 2001-812940	A 20010327
				US 2001-812944	A 20010327
				US 2001-812945	A 20010327
				US 2001-25947	A 20011226
				WO 2002-US8836	W 20020325

EP 1408946	A2	20040421	EP 2002-719311	20020325
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
			US 2001-812940	A 20010327
			US 2001-812944	A 20010327
			US 2001-812945	A 20010327
			US 2001-25947	A 20011226
			WO 2002-US8836	W 20020325
FAN 2002:755220				
PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----
PI US 2002143052	A1	20021003	US 2001-812945	20010327
CA 2442366	AA	20021003	CA 2002-2442366	20020325
			US 2001-812940	A 20010327
			US 2001-812944	A 20010327
			US 2001-812945	A 20010327
			US 2001-25947	A 20011226
			WO 2002-US8836	W 20020325
WO 2002076941	A2	20021003	WO 2002-US8836	20020325
WO 2002076941	A3	20040212		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
			US 2001-812940	A1 20010327
			US 2001-812944	A1 20010327
			US 2001-812945	A1 20010327
			US 2001-25947	A1 20011226
AU 2002250401	A1	20021008	AU 2002-250401	20020325
			US 2001-812940	A 20010327
			US 2001-812944	A 20010327
			US 2001-812945	A 20010327
			US 2001-25947	A 20011226
			WO 2002-US8836	W 20020325
EP 1408946	A2	20040421	EP 2002-719311	20020325
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
			US 2001-812940	A 20010327
			US 2001-812944	A 20010327
			US 2001-812945	A 20010327
			US 2001-25947	A 20011226
			WO 2002-US8836	W 20020325
US 2003125306	A1	20030703	US 2002-318225	20021213
			US 2001-812945	A3 20010327
US 2005107348	A1	20050519	US 2004-19303	20041223
			US 2001-812945	A3 20010327
US 2005171208	A1	20050804	US 2005-59377	20050217
			US 2001-812945	A3 20010327
FAN 2002:755255				
PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----
PI US 2002143196	A1	20021003	US 2001-812944	20010327
US 6495719	B2	20021217		
CA 2442366	AA	20021003	CA 2002-2442366	20020325
			US 2001-812940	A 20010327
			US 2001-812944	A 20010327
			US 2001-812945	A 20010327



			US 2001-25947	A	20011226
			WO 2002-US8836	W	20020325
WO 2002076941	A2	20021003	WO 2002-US8836		20020325
WO 2002076941	A3	20040212			
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
			US 2001-812940	A1	20010327
			US 2001-812944	A1	20010327
			US 2001-812945	A1	20010327
			US 2001-25947	A1	20011226
AU 2002250401	A1	20021008	AU 2002-250401		20020325
			US 2001-812940	A	20010327
			US 2001-812944	A	20010327
			US 2001-812945	A	20010327
			US 2001-25947	A	20011226
			WO 2002-US8836	W	20020325
EP 1408946	A2	20040421	EP 2002-719311		20020325
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
			US 2001-812940	A	20010327
			US 2001-812944	A	20010327
			US 2001-812945	A	20010327
			US 2001-25947	A	20011226
			WO 2002-US8836	W	20020325
US 2003083521	A1	20030501	US 2002-307321		20021202
			US 2001-812944	A3	20010327
FAN 2004:453179					
PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
-----	-----	-----	-----	-----	
PI WO 2004046104	A2	20040603	WO 2003-US36981		20031119
WO 2004046104	A3	20040805			
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
			US 2002-427567P	P	20021120
CA 2506504	AA	20040603	CA 2003-2506504		20031119
			US 2002-427567P	P	20021120
			WO 2003-US36981	W	20031119
AU 2003291097	A1	20040615	AU 2003-291097		20031119
			US 2002-427567P	P	20021120
			WO 2003-US36981	W	20031119
EP 1567142	A2	20050831	EP 2003-783686		20031119
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
			US 2002-427567P	P	20021120
			WO 2003-US36981	W	20031119
JP 2006508986	T2	20060316	JP 2004-553939		20031119
			US 2002-427567P	P	20021120

OS MARPAT 141:167803

AB Lung disease, such as cystic fibrosis, chronic obstructive pulmonary disease, asthma, or acute and chronic bronchitis, can be treated with an oxyamide-containing compound Preparation of e.g. 5-phenyl-2,4-pentadienoylhydroxamic acid is described.

L9 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN

TI A preparation of unsaturated hydroxamic acid derivatives useful as histone deacetylase inhibitors

AN 2004:453179 CAPLUS

DN 141:23197

TI A preparation of unsaturated hydroxamic acid derivatives useful as histone deacetylase inhibitors

IN Wiech, Norbert L.; Lan-Hargest, Hsuan-yin

PA Circagen Pharmaceutical, USA; Beacon Laboratories

SO PCT Int. Appl., 27 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004046104	A2	20040603	WO 2003-US36981	20031119
	WO 2004046104	A3	20040805		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2506504	AA	20040603	US 2002-427567P	P 20021120
				CA 2003-2506504	20031119
				US 2002-427567P	P 20021120
				WO 2003-US36981	W 20031119
	AU 2003291097	A1	20040615	AU 2003-291097	20031119
				US 2002-427567P	P 20021120
				WO 2003-US36981	W 20031119
	EP 1567142	A2	20050831	EP 2003-783686	20031119
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
				US 2002-427567P	P 20021120
				WO 2003-US36981	W 20031119
	JP 2006508986	T2	20060316	JP 2004-553939	20031119
				US 2002-427567P	P 20021120
				WO 2003-US36981	W 20031119

## PATENT FAMILY INFORMATION:

FAN 2002:754352


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002076941	A2	20021003	WO 2002-US8836	20020325
	WO 2002076941	A3	20040212		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,			

KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,  
GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,  
GN, GQ, GW, ML, MR, NE, SN, TD, TG

			US 2001-812940	A1	20010327
			US 2001-812944	A1	20010327
			US 2001-812945	A1	20010327
			US 2001-25947	A1	20011226
US 2002143196	A1	20021003	US 2001-812944		20010327
US 6495719	B2	20021217			
US 2002143052	A1	20021003	US 2001-812945		20010327
US 2002143037	A1	20021003	US 2001-25947		20011226
			US 2001-812940	B1	20010327
CA 2442366	AA	20021003	CA 2002-2442366		20020325
			US 2001-812940	A	20010327
			US 2001-812944	A	20010327
			US 2001-812945	A	20010327
			US 2001-25947	A	20011226
			WO 2002-US8836	W	20020325
AU 2002250401	A1	20021008	AU 2002-250401		20020325
			US 2001-812940	A	20010327
			US 2001-812944	A	20010327
			US 2001-812945	A	20010327
			US 2001-25947	A	20011226
			WO 2002-US8836	W	20020325
EP 1408946	A2	20040421	EP 2002-719311		20020325
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			US 2001-812940	A	20010327
			US 2001-812944	A	20010327
			US 2001-812945	A	20010327
			US 2001-25947	A	20011226
			WO 2002-US8836	W	20020325
FAN 2002:755220					
PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI US 2002143052	A1	20021003	US 2001-812945		20010327
CA 2442366	AA	20021003	CA 2002-2442366		20020325
			US 2001-812940	A	20010327
			US 2001-812944	A	20010327
			US 2001-812945	A	20010327
			US 2001-25947	A	20011226
			WO 2002-US8836	W	20020325
WO 2002076941	A2	20021003	WO 2002-US8836		20020325
WO 2002076941	A3	20040212			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			US 2001-812940	A1	20010327
			US 2001-812944	A1	20010327
			US 2001-812945	A1	20010327
			US 2001-25947	A1	20011226
AU 2002250401	A1	20021008	AU 2002-250401		20020325
			US 2001-812940	A	20010327
			US 2001-812944	A	20010327
			US 2001-812945	A	20010327
			US 2001-25947	A	20011226

EP 1408946	A2	20040421	WO 2002-US8836	W	20020325
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			EP 2002-719311		20020325
			US 2001-812940	A	20010327
			US 2001-812944	A	20010327
			US 2001-812945	A	20010327
			US 2001-25947	A	20011226
			WO 2002-US8836	W	20020325
US 2003125306	A1	20030703	US 2002-318225		20021213
			US 2001-812945	A3	20010327
US 2005107348	A1	20050519	US 2004-19303		20041223
			US 2001-812945	A3	20010327
US 2005171208	A1	20050804	US 2005-59377		20050217
			US 2001-812945	A3	20010327
FAN 2002:755255					
PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
-----	-----	-----	-----		-----
PI US 2002143196	A1	20021003	US 2001-812944		20010327
US 6495719	B2	20021217			
CA 2442366	AA	20021003	CA 2002-2442366		20020325
			US 2001-812940	A	20010327
			US 2001-812944	A	20010327
			US 2001-812945	A	20010327
			US 2001-25947	A	20011226
			WO 2002-US8836	W	20020325
WO 2002076941	A2	20021003	WO 2002-US8836		20020325
WO 2002076941	A3	20040212			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
			US 2001-812940	A1	20010327
			US 2001-812944	A1	20010327
			US 2001-812945	A1	20010327
			US 2001-25947	A1	20011226
AU 2002250401	A1	20021008	AU 2002-250401		20020325
			US 2001-812940	A	20010327
			US 2001-812944	A	20010327
			US 2001-812945	A	20010327
			US 2001-25947	A	20011226
			WO 2002-US8836	W	20020325
EP 1408946	A2	20040421	EP 2002-719311		20020325
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
			US 2001-812940	A	20010327
			US 2001-812944	A	20010327
			US 2001-812945	A	20010327
			US 2001-25947	A	20011226
			WO 2002-US8836	W	20020325
US 2003083521	A1	20030501	US 2002-307321		20021202
			US 2001-812944	A3	20010327
FAN 2004:701812					
PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
-----	-----	-----	-----		-----
PI US 2004167184	A1	20040826	US 2003-715377		20031119
			US 2001-812940	B1	20010327

US 2002143037	A1	20021003	US 2001-25947	A2 20011226
			US 2002-427567P	P 20021120
OS MARPAT 141:23197			US 2001-25947	20011226
GI			US 2001-812940	B1 20010327



AB The invention relates to a preparation of amides of formula I [wherein: A is (hetero)cycloalk(en)yl, (hetero)aryl, etc.; Y1 and Y2 are independently selected from CH2, O, S, OC(O)O, NH, or -NHC(O)O-, etc.; L is (un)substituted C2-12 hydrocarbon chain optionally containing one double bond, at least one triple bond, or at least one double bond and one triple bond; R1 is H, alk(en/yn)yl, alkoxy, OH, etc.; R2 is H, alkyl, hydroxyalkyl, or haloalkyl, etc.], useful as histone deacetylase inhibitors. The invented compds. are claimed to be useful for the treatment of cystic fibrosis, chronic obstructive pulmonary disease, and asthma, etc. The prepared compds. were screened in cystic fibrosis assay (example 4 and 5) and for bronchial epithelial electrolyte transport (example 6). The mean inhibition of sodium transport for 7-phenyl-2,4,6-heptatrienoylhydroxamic acid was 69.2%. Inhibition of sodium transport by 7-phenyl-2,4,6-heptatrienoylhydroxamic acid was concentration-dependent with a half-maximal inhibitory concentration of 11.9  $\mu\text{M}$ . For instance, PhCH:CHCH:CHC(O)NHOH was prepared from PhCH:CHCH:CHCO2H and NH2OH•HCl in anhydrous DMF (example 2, no yield data).

=> logoff hold

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
29.45	203.56

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-2.25	-2.25

CA SUBSCRIBER PRICE

SESSION WILL BE HELD FOR 60 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 12:16:28 ON 21 SEP 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:

\*\*\*\*\* RECONNECTED TO STN INTERNATIONAL \*\*\*\*\*  
 SESSION RESUMED IN FILE 'CAPLUS' AT 12:39:47 ON 21 SEP 2006  
 FILE 'CAPLUS' ENTERED AT 12:39:47 ON 21 SEP 2006  
 COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
------------	-------

FULL ESTIMATED COST	ENTRY 29.45	SESSION 203.56
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
CA SUBSCRIBER PRICE	ENTRY -2.25	SESSION -2.25
=> logoff hold		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
FULL ESTIMATED COST	ENTRY 29.91	SESSION 204.02
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
CA SUBSCRIBER PRICE	ENTRY -2.25	SESSION -2.25

SESSION WILL BE HELD FOR 60 MINUTES  
STN INTERNATIONAL SESSION SUSPENDED AT 12:40:39 ON 21 SEP 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:

\* \* \* \* \* RECONNECTED TO STN INTERNATIONAL \* \* \* \* \*  
SESSION RESUMED IN FILE 'CAPLUS' AT 12:41:06 ON 21 SEP 2006  
FILE 'CAPLUS' ENTERED AT 12:41:06 ON 21 SEP 2006  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
FULL ESTIMATED COST	ENTRY 30.37	SESSION 204.48
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
CA SUBSCRIBER PRICE	ENTRY -2.25	SESSION -2.25

=> d his

(FILE 'HOME' ENTERED AT 12:04:22 ON 21 SEP 2006)

FILE 'REGISTRY' ENTERED AT 12:10:08 ON 21 SEP 2006

```

L1          STRUCTURE UPLOADED
L2          50 SEARCH L1 SSS SAM
L3          853427 0
L4          STRUCTURE UPLOADED
L5          0 SEARCH L4 SSS SAM
L6          11 SEARCH L4 SSS FULL

```

FILE 'CAPLUS' ENTERED AT 12:13:53 ON 21 SEP 2006

```

L7          104 L6
L8          37979 ASTHMA OR BRONCHITIS OR COPD
L9          3 L7 AND L8

```

=> save temp l7 hydroxamfinds/a  
HYDROXAMFINDS/A IS NOT A VALID SAVED NAME  
Enter the name you wish to use for the saved query,  
answer set, or L-number list. The name must:

1. Begin with a letter,
2. Have 1-12 characters,
3. Contain only letters (A-Z) and numbers (0-9),
4. End with /Q for a query (search profile, structure, or screen set), /A for an answer set, or /L for an L-number list.
5. Not already be in use as a saved name,
6. Not be END, SAV, SAVE, SAVED
7. Not have the form of an L-number (Lnnn).

ENTER NAME OR (END):hdrxamfnds/a

ANSWER SET L7 HAS BEEN SAVED AS 'HDRXAMFND/A'

=> sodium

1060363 SODIUM

35 SODIUMS

L10 1060372 SODIUM

(SODIUM OR SODIUMS)

=> transport

708922 TRANSPORT

5830 TRANSPORTS

L11 711245 TRANSPORT

(TRANSPORT OR TRANSPORTS)

=> 17 and l11

L12 3 L7 AND L11

=> l12 not 19

L13 1 L12 NOT L9

=> d l13 ti fbib abs

L13 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN

TI Topical use of valproic acid, alone or with other agents, for the prevention or treatment of skin disorders

AN 2004:1154310 CAPLUS

DN 142:69220

TI Topical use of valproic acid, alone or with other agents, for the prevention or treatment of skin disorders

IN Pelicci, Pier Giuseppe; Minucci, Saverio; Costanzo, Antonio; Chimenti, Sergio; Nistico, Steven Paul; Paolino, Donatella

PA G2M Cancer Drugs AG, Germany

SO Eur. Pat. Appl., 40 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1491188	A1	20041229	EP 2003-14278	20030625
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	AU 2004251434	A1	20050106	AU 2004-251434	20040623
				EP 2003-14278	A 20030625
				WO 2004-EP6789	W 20040623
	AU 2004251435	A1	20050106	AU 2004-251435	20040623
				EP 2003-14278	A 20030625
				WO 2004-EP6797	W 20040623
	CA 2531101	AA	20050106	CA 2004-2531101	20040623
				EP 2003-14278	A 20030625
				WO 2004-EP6789	W 20040623
	CA 2531107	AA	20050106	CA 2004-2531107	20040623
				EP 2003-14278	A 20030625

WO 2005000289 A1 20050106 WO 2004-EP6797 W 20040623  
 WO 2004-EP6789 20040623  
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,  
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,  
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,  
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,  
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,  
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,  
 SN, TD, TG

WO 2005000282 A2 20050106 EP 2003-14278 A 20030625  
 WO 2004-EP6797 20040623  
 WO 2005000282 A3 20050428  
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,  
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,  
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,  
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,  
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,  
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,  
 SN, TD, TG

EP 1635808 A1 20060322 EP 2003-14278 A 20030625  
 EP 2004-740209 20040623  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK

EP 1635798 A2 20060322 EP 2003-14278 A 20030625  
 WO 2004-EP6789 W 20040623  
 EP 2004-740216 20040623  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK

US 2006160897 A1 20060720 EP 2003-14278 A 20030625  
 WO 2004-EP6797 W 20040623  
 US 2005-275258 20051221  
 EP 2003-14278 A 20030625  
 WO 2004-EP6789 A1 20040623

OS MARPAT 142:69220

AB The invention relates to a topically applicable formulation containing valproic acid or a derivative thereof which can be used alone or in combination with topically applicable formulations of retinoids or of nuclear receptor ligands, or of chemotherapeutic agents (e.g. 5-Fluorouracil). The formulation is useful for the topical treatment of cancerous skin disorders, e.g. basal cell carcinoma, squamous cell carcinoma, keratoakantoma, Bowen disease, cutaneous T-Cell lymphoma, and also for the topical treatment of premalignant lesions, and of inflammation of the skin and/or mucosa. The invention also relates to the use of this topically applicable formulation for protection from UV light and for the treatment of sunburn. The invention includes the use of valproic acid for the manufacture of a clin. used medicament for the topical treatment of the above human diseases.

RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> logoff hold

COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE

ENTRY

39.77

TOTAL

SESSION

213.88



DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

CA SUBSCRIBER PRICE

ENTRY  
-3.00

SESSION  
-3.00

SESSION WILL BE HELD FOR 60 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 12:44:58 ON 21 SEP 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 FEB 27 New STN AnaVist pricing effective March 1, 2006  
NEWS 4 MAY 10 CA/CAPLUS enhanced with 1900-1906 U.S. patent records  
NEWS 5 MAY 11 KOREAPAT updates resume  
NEWS 6 MAY 19 Derwent World Patents Index to be reloaded and enhanced  
NEWS 7 MAY 30 IPC 8 Rolled-up Core codes added to CA/CAPLUS and  
USPATFULL/USPAT2  
NEWS 8 MAY 30 The F-Term thesaurus is now available in CA/CAPLUS  
NEWS 9 JUN 02 The first reclassification of IPC codes now complete in  
INPADOC  
NEWS 10 JUN 26 TULSA/TULSA2 reloaded and enhanced with new search and  
and display fields  
NEWS 11 JUN 28 Price changes in full-text patent databases EPFULL and PCTFULL  
NEWS 12 JUL 11 CHEMSAFE reloaded and enhanced  
NEWS 13 JUL 14 FSTA enhanced with Japanese patents  
NEWS 14 JUL 19 Coverage of Research Disclosure reinstated in DWPI  
NEWS 15 AUG 09 INSPEC enhanced with 1898-1968 archive  
NEWS 16 AUG 28 ADISCTI Reloaded and Enhanced  
NEWS 17 AUG 30 CA(SM)/CAPLUS(SM) Austrian patent law changes  
NEWS 18 SEP 11 CA/CAPLUS enhanced with more pre-1907 records  
NEWS 19 SEP 21 CA/CAPLUS fields enhanced with simultaneous left and right  
truncation  
  
NEWS EXPRESS JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT  
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.  
  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8  
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may

result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 14:26:35 ON 21 SEP 2006

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'CAPLUS' ENTERED AT 14:26:47 ON 21 SEP 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 21 Sep 2006 VOL 145 ISS 13

FILE LAST UPDATED: 20 Sep 2006 (20060920/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> leukotriene

13967 LEUKOTRIENE

7800 LEUKOTRIENES

L1 16083 LEUKOTRIENE

(LEUKOTRIENE OR LEUKOTRIENES)

=> sodium(l)transport

1060363 SODIUM

35 SODIUMS

1060372 SODIUM

(SODIUM OR SODIUMS)

708922 TRANSPORT

5830 TRANSPORTS

711245 TRANSPORT

(TRANSPORT OR TRANSPORTS)

L2 43283 SODIUM(L)TRANSPORT

=> l1(l)l2

L3 26 L1(L)L2

=> d 13 20-26 ti

L3 ANSWER 20 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN

TI Regulation of renal transport processes and hemodynamics by macrophages and lymphocytes

L3 ANSWER 21 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN

TI Studies on the uptake, binding and metabolism of leukotriene B4 by human

neutrophils

- L3 ANSWER 22 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN  
TI Sodium/hydrogen ion exchange modulates the production of leukotriene B4 by human neutrophils
- L3 ANSWER 23 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN  
TI Leukotriene D4-induced increases in the cytoplasmic pH of human myelocytic leukocytes
- L3 ANSWER 24 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN  
TI Electrophysiological consequences of leukotrienes applied on isolated rat retina
- L3 ANSWER 25 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN  
TI The effect of cyclic nucleotides and eicosanoids on sodium and potassium transport in human red cells
- L3 ANSWER 26 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN  
TI Similarities in the mechanisms by which formyl-methionyl-leucyl-phenylalanine, arachidonic acid and leukotriene B4 increase calcium and sodium influxes in rabbit neutrophils

=> epitheliumj

- 0 EPITHELIUMJ  
L4 0 EPITHELIUMJ

=> epithelium

- 98761 EPITHELIUM  
83 EPITHELIUMS  
12896 EPITHELIA  
L5 104174 EPITHELIUM  
(EPITHELIUM OR EPITHELIUMS OR EPITHELIA)

=> l3 and l5

- L6 1 L3 AND L5

=> d l6 ti fbib abs

- L6 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN  
TI Modulation of ion transport in cultured rabbit tracheal epithelium by lipoxygenase metabolites  
AN 1993:33455 CAPLUS  
DN 118:33455  
TI Modulation of ion transport in cultured rabbit tracheal epithelium by lipoxygenase metabolites  
AU Egan, M. E.; Wagner, M. H.; Zeitlin, P. L.; Guggino, W. B.  
CS Sch. Med., Johns Hopkins Univ., Baltimore, MD, USA  
SO American Journal of Respiratory Cell and Molecular Biology (1992), 7(5), 500-6  
CODEN: AJRBEL; ISSN: 1044-1549  
DT Journal  
LA English  
AB Lipoxygenase metabolites influence ion movement and fluid balance in the airways. The effects of nordihydroguaiaretic acid (NDGA), a general inhibitor of the lipoxygenase pathway, on Na<sup>+</sup> and Cl<sup>-</sup> secretion in cultured tracheal epithelial cells from adult rabbits were studied by short-circuit current (Isc) and radioactive tracer flux expts. NDGA inhibition of leukotriene release in freshly isolated rabbit tracheal epithelial cells was assayed by a 3H peptidyl-leukotriene RIA. At 3  $\mu$ M NDGA caused a 91% reduction of leukotriene release. In unstimulated cultures, Cl<sup>-</sup> secretion (furosemide-inhibited fraction of Isc) was 11.1  $\mu$ A/cm<sup>2</sup>

and was unchanged in the presence of NDGA. Epinephrine-stimulated Cl<sup>-</sup> secretion increased I<sub>sc</sub> by 12.2  $\mu$ A/cm<sup>2</sup>. This stimulation was unchanged by pretreatment with NDGA, suggesting that inhibition of the lipoxxygenase pathway did not affect Cl<sup>-</sup> secretion. In unstimulated cultures, Na<sup>+</sup> absorption (amiloride-inhibited portion of I<sub>sc</sub>) was 10.7  $\mu$ A/cm<sup>2</sup> and was reduced by 79% in the presence of NDGA, suggesting that inhibition of the lipoxxygenase pathway was associated with inhibition of Na<sup>+</sup> absorption. Radioactive tracer flux expts. supported these findings. Exogenous LTD4 and LTC4 were added to cells pretreated with NDGA, and Na<sup>+</sup> absorption was restored to 76% and 70% of control, resp. In addition, LTD4 and LTC4 were added to cells without prior inhibition of the lipoxxygenase pathway to NDGA and resulted in an increase in Cl<sup>-</sup> secretion. This increase could be inhibited by pretreatment with indomethacin, an inhibitor of prostaglandin production. Inhibition of the lipoxxygenase pathway with NDGA is associated with a reduction in Na<sup>+</sup> absorption, whereas addnl. LTD4 and LTC4 is associated with a stimulation of Cl<sup>-</sup> secretion. Thus, the lipoxxygenase pathway has a dual effect on ion transport, modulating baseline Na<sup>+</sup> absorption and stimulating Cl<sup>-</sup> secretion in rabbit tracheal epithelial cells.

=> logoff hold

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
18.02	18.23

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-0.75	-0.75

CA SUBSCRIBER PRICE

SESSION WILL BE HELD FOR 60 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 14:31:02 ON 21 SEP 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1	Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	"Ask CAS" for self-help around the clock
NEWS 3 FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS 4 MAY 10	CA/CAPLUS enhanced with 1900-1906 U.S. patent records
NEWS 5 MAY 11	KOREAPAT updates resume
NEWS 6 MAY 19	Derwent World Patents Index to be reloaded and enhanced
NEWS 7 MAY 30	IPC 8 Rolled-up Core codes added to CA/CAPLUS and USPATFULL/USPAT2
NEWS 8 MAY 30	The F-Term thesaurus is now available in CA/CAPLUS
NEWS 9 JUN 02	The first reclassification of IPC codes now complete in INPADOC
NEWS 10 JUN 26	TULSA/TULSA2 reloaded and enhanced with new search and display fields
NEWS 11 JUN 28	Price changes in full-text patent databases EPFULL and PCTFULL
NEWS 12 JUL 11	CHEMSAFE reloaded and enhanced